[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5618
1. Leite JL, Morari EC, Granja F, Campos GM, Guilhen AC, Ward LS: Influence of the glutathione s-transferase gene polymorphisms on the susceptibility to basal cell skin carcinoma. Rev Med Chil; 2007 Mar;135(3):301-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the glutathione s-transferase gene polymorphisms on the susceptibility to basal cell skin carcinoma.
  • BACKGROUND: The identification of groups at high risk is fundamental to determine preventive strategies for skin cancer.
  • AIMS: To ascertain the influence and potential interactions of several polymorphisms of genes encoding four important antioxidant GST enzymes in the susceptibility to cancer among Brazilians.
  • MATERIAL AND METHODS: We compared the genotypes of Glutathione S-Transferase mu, theta, pi and omega (GSTM1, GSTT1, GSTP1 and GSTO2) in a group of 102 patients with skin lesions and 124 controls.
  • RESULTS: Patients with Basal Cell Skin Carcinoma (BCC) presented the combined GSTM1-GSTT1+ genotype more frequently (49.1%) than controls (29.8%) (Fisher test; p=0.04), conferring a 2.273 (Odds Ratio; 95% CI=1.199-4.308) higher risk for BCC.
  • CONCLUSIONS: The GST profile may help identify Brazilian individuals at higher risk for BCC.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Genetic Predisposition to Disease / genetics. Glutathione Transferase / genetics. Polymorphism, Genetic / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505575.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTO2 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


2. Patidar S: Excision of Basal cell carcinoma with radio frequency ablation. J Cutan Aesthet Surg; 2008 Jan;1(1):29-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excision of Basal cell carcinoma with radio frequency ablation.
  • Basal cell carcinoma is usually treated by excision, or by ablative methods such as cryosurgery and laser.
  • We describe treament of basal cell carcinoma by radiofrequency device.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20300339.001).
  • [ISSN] 0974-5157
  • [Journal-full-title] Journal of cutaneous and aesthetic surgery
  • [ISO-abbreviation] J Cutan Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2840884
  • [Keywords] NOTNLM ; Ablation / Basal cell carcinoma / Radiofrequency
  •  go-up   go-down


3. Li X, Gast A, Rudnai P, Gurzau E, Koppova K, Hemminki K, Kumar R: ARLTS1 polymorphisms and basal cell carcinoma of the skin. Hered Cancer Clin Pract; 2007;5(1):25-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARLTS1 polymorphisms and basal cell carcinoma of the skin.
  • Polymorphisms in the ARLTS1 gene, a member of the Ras super-family, have been associated with susceptibility in different cancer types.
  • The involvement of the gene in apoptotic signalling motivated us to study the role of ARLTS1 polymorphic variations in basal cell carcinoma of the skin (BCC).
  • In a case-control study, 529 cases diagnosed with BCC and 533 controls from Hungary, Romania and Slovakia were genotyped for the S99S (297G>A), P131L (392C>T), L132L (396G>C), C148R (442T>C) and W149X (446G>A) polymorphisms in the ARLTS1 gene.
  • No significant association between any of the single nucleotide polymorphisms (SNP) and risk of BCC (S99S, odds ratio (OR) 0.96, 95% confidence interval (CI) 0.601.53; P131L, OR 1.31 95%CI 0.742.31; L132L, OR 0.50, 95%CI 0.027.07; C148R, OR 0.50, 95%CI 0.691.18; and W149X, OR 1.01, 95%CI 0.372.79) was detected.
  • Furthermore, no significant difference in the distribution of haplotypes due to five polymorphisms in the ARLTS1 gene was found between the BCC cases and controls.
  • Our data rule out an association between variants in ARLTS1 and risk of BCC in the investigated population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Nov 15;131C(1):82-92 [15468170.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):468-73 [15761425.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10287-91 [17079447.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1573-6 [16581122.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • [Cites] Semin Cancer Biol. 2004 Feb;14(1):63-9 [14757536.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Arch Dermatol. 2001 Nov;137(11):1486-92 [11708952.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6640-8 [11559527.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2870-7 [11306461.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):172-5 [16488076.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1736-7 [16646072.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(1):59-62 [16570116.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1676-81 [16501254.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2505-8 [16353159.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1667-76 [15843669.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):850-60 [15516958.001]
  • (PMID = 19723348.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2736660
  •  go-up   go-down


Advertisement
4. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F: Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma. Actas Dermosifiliogr; 2010 Sep;101(7):622-628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma.
  • [Transliterated title] Análisis de costes de la cirugía micrográfica de Mohs en el carcinoma basocelular facial de alto riesgo.
  • INTRODUCTION: Mohs micrographic surgery (MMS) is the treatment of choice for high-risk facial basal cell carcinoma (BCC) as it offers the greatest chance of cure with maximum preservation of healthy tissue.
  • OBJECTIVES: To determine the cost of MMS with fresh tissue to treat high-risk facial BCC and compare this to the estimated cost of conventional surgery in a Spanish public hospital.
  • MATERIAL AND METHODS: Cross-sectional study of a consecutive series of patients with high-risk facial BCC who underwent MMS at the Department of Dermatology at Hospital Costa del Sol in Malaga, Spain between July 2006 and December 2007.
  • RESULTS: Seventy-nine patients (mean age, 62 years) with 81 high-risk facial BCCs, 97.5% of which were primary tumors, underwent MMS.
  • Histology showed that 64% of the tumors were infiltrative or micronodular carcinomas.
  • Tumor-free margins were achieved in all patients, with no more than 2 stages required in 88% of the cases.
  • The most common surgical reconstruction techniques were direct closure (21%) and closure with a local skin flap or graft (71%); the corresponding estimates for conventional surgery were 2% and 89%, respectively.
  • CONCLUSIONS: MMS is a viable, effective technique that does not generate significantly higher costs than conventional surgery in selected patients with high-risk facial BCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y AEDV. All rights reserved.
  • (PMID = 28709544.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliograficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Análisis de costes / Cirugía micrográfica / Cost analysis / Cost-effectiveness / Coste/beneficio / Micrographic surgery / Mohs
  •  go-up   go-down


5. Corrêa Mde P, Ferreira AP, Gollner AM, Rodrigues MF, Guerra MC: [Markers expression of cell proliferation and apoptosis in basal cell carcinoma]. An Bras Dermatol; 2009 Nov-Dec;84(6):606-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Markers expression of cell proliferation and apoptosis in basal cell carcinoma].
  • [Transliterated title] Expressão de marcadores de proliferação celular e apoptose em carcinoma basocelular.
  • BACKGROUND: - Basal cell carcinoma is the most common form of human cancer.
  • OBJECTIVE - To correlate markers expression of apoptosis (p53 and bcl-2) and cell proliferation (Ki-67 and PCNA) with histological indicators of tumor severity.
  • METHODS - Five samples of the nodular, morpheaform and superficial types of carcinoma were studied, respectively.One control group with three lesion-free patients was also included in the study.
  • The Mann-Whitney test was used to compare these markers expression with the manifestation form of basal cell carcinoma.
  • RESULTS - Bcl-2 expression was significant in basal cell carcinomas said to be aggressive (morpheaform and nodular types).
  • Of the studied tumors, 66.7% (n =10) strongly expressed p53.Our results show a greater expression of Ki-67 in nodular and superficial basal cell carcinoma, with no expression in the controls.
  • CONCLUSION - The findings allow us to conclude that Bcl-2 and p53 show a tendency to indicate the severity of basal cell carcinoma.
  • Also, PCNA was not a good marker of cell proliferation.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Cell Proliferation. Skin Neoplasms / chemistry. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191172.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Rong Y, Welsh JS: Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer treatmenta). Med Phys; 2010 Oct;37(10):5509-5517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer treatmenta).
  • PURPOSE: The Xoft Axxent<sup>®</sup> x-ray source has been used for treating nonmelanoma skin cancer since the surface applicators became clinically available in 2009.
  • The TG-61 in-air method was used as a guideline for acquiring nominal dose-rate output at the skin surface.
  • GafChromic<sup>®</sup> EBT films were used for testing the properties of the treatment fields with the skin applicators.
  • Patients with basal cell or squamous cell carcinoma were treated with eBx using a calibrated Xoft system with the low-energy x-ray source and the skin applicators.
  • RESULTS: The average nominal dose-rate output at the skin surface for the 35 mm applicator is 1.35 Gy/min with ±5% variation for 16 sources.
  • The output factor needs to be measured for each case with varying shapes of cutouts.
  • CONCLUSIONS: Together with TG-61, the authors' methodology provides comprehensive calibration procedures for medical physicists for using the Xoft eBx system and skin applicators for nonmelanoma skin cancer treatments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524537.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brachytherapy / Calibration / Cancer / Dosimetry / Dosimetry/exposure assessment / Ionization chambers / Lead / Radiation treatment / Skin / Standards and calibration / Surface treatments / Therapeutic applications, including brachytherapy / X-rays / basal cell carcinoma / biomedical equipment / brachytherapy / calibration / cancer / dosimetry / electronic brachytherapy / nonmelanoma skin cancer / skin / squamous cell carcinoma / surface applicator
  •  go-up   go-down


7. Patel R, Adsay V, Andea A: Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma. Rare Tumors; 2010;2(1):e8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma.
  • Merkel cell carcinoma (MCC) or primary cutaneous neuroendocrine carcinoma is a malignant tumor considered to demonstrate differentiation towards Merkel cells that are present at the base of the epidermis or around the apical end of some hair follicles and are thought to play a yet uncertain role in sensory transduction.
  • Here we present the case of a 54- year old female with a basal cell carcinoma (BCC) of the skin with neuroendocrine features (positivity for chromogranin) that has evolved during multiple recurrences and radiotherapy into a high-grade neuroendocrine carcinoma with morphological and immunohistochemical features of MCC (trabecular and nesting arrangement, positivity for chromogranin, cytokeratin 20, neuron specific enolase, and also neurosecretory granules on electron microscopy).
  • The progression from a chromogranin positive basal cell carcinoma of the skin, to a high-grade neuroendocrine carcinoma demonstrates the potential for cross differentiation among skin tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139953.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994488
  • [Keywords] NOTNLM ; Merkel cell carcinoma / basal cell carcinoma / neuroendocrine
  •  go-up   go-down


8. Paavilainen V, Tuominen J, Aho VV, Saari KM: Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland. Eur J Ophthalmol; 2007 Jul-Aug;17:494-500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland.
  • : . PURPOSE: Basal cell carcinoma (BCC) is the most common skin cancer of the eyelid, showing an increasing incidence in the white population.
  • The authors studied the clinical characteristics and the treatment results of BCC of the eyelid in southwestern Finland during 1977-1997.
  • METHODS: The authors reviewed the case records of 191 patients with BCC of the eyelids treated at the Turku University Eye Clinic during 1977-1997.
  • RESULTS: The 191 patients had altogether 194 BCC tumors of the eyelid with the mean diameter of the tumor being smaller than 10 mm in 77.3% of cases.
  • Of the 194 BCC tumors of the eyelid 16.0% showed recurrence, and the recurrence rate of all surgically treated tumors was 13.7%.
  • In this study 61 patients (31.9%) developed other malignancies than the BCC of the eyelid including 28 patients (14.7 %) with carcinoma in other locations than skin.
  • CONCLUSIONS: Incompletely removed BCCs of the eyelid showed only 18.9% recurrence rate during the follow-up time.
  • On the other hand, BCCs of the eyelid should not be underestimated because of the rather high total recurrence rate.
  • The frequency of 31.9% of other malignancies than BCC of the eyelid is remarkably high and requires special attention from the ophthalmologist taking care of the patient with BCC of the eyelid.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221540.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Pinto Pereira SM, Hipwell JH, McCormack VA, Tanner C, Moss SM, Wilkinson LS, Khoo LAL, Pagliari C, Skippage PL, Kliger CJ, Hawkes DJ, Dos Santos Silva IM: Automated registration of diagnostic to prediagnostic x-ray mammograms: Evaluation and comparison to radiologists' accuracy. Med Phys; 2010 Sep;37(9):4530-4539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: X-ray mammograms were simulated from MRIs of 20 women using finite element methods for modeling breast compressions and employing a MRI/x-ray appearance change model.
  • Five mammography film readers independently identified landmarks (tumor, nipple, and usually two other normal features) on pairs of diagnostic and corresponding prediagnostic digitized images from 52 breast cancer cases.
  • Registration accuracy was sensitive to the type of landmark and the amount of breast density.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524565.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Digital mammography / Film mammography / Finite element calculations / Image analysis / MRI / Magnetic resonance imaging / Mammography / Medical X-ray imaging / Medical imaging / Radiography / Registration / Tissues / X-ray imaging / affine transforms / biological organs / biomedical MRI / breast cancer / cancer / diagnostic radiography / finite element analysis / image registration / mammographic density / mammography / medical image processing / registration algorithms / tumours
  •  go-up   go-down


10. Zur Hausen A: [Merkel cell polyomavirus in the pathogenesis of non-melanoma skin cancer]. Pathologe; 2009 Dec;30 Suppl 2:217-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell polyomavirus in the pathogenesis of non-melanoma skin cancer].
  • Merkel cell carcinoma (MCC) is a very aggressive neuroendocrine carcinoma of the skin.
  • The recently identified Merkel cell polyomavirus (MCPyV) is present in the majority of MCCs.
  • To elucidate a possible role of MCPyV in the pathogenesis of other non-melanoma skin cancers (NMSC), i.e. squamous cell carcinoma, Bowen's disease and basal cell carcinoma we tested a group of these tumors in immunosuppressed and immunocompetent patients.
  • Although MCPyV is present in the tumor cells of squamous cell carcinoma, Bowen's disease and basal cell skin carcinoma, further investigations into the role of MCPyV in the pathogenesis of these tumors is needed.
  • [MeSH-major] Bowen's Disease / genetics. Bowen's Disease / virology. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / virology. Carcinoma, Merkel Cell / genetics. Carcinoma, Merkel Cell / virology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / virology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Viral / genetics. Merkel Cells / pathology. Merkel Cells / virology. Polyomavirus / genetics. Polyomavirus Infections / genetics. Polyomavirus Infections / virology. Skin Neoplasms / genetics. Skin Neoplasms / virology
  • [MeSH-minor] Antigens, Viral, Tumor / genetics. DNA Mutational Analysis. Genes, Viral / genetics. Humans. In Situ Hybridization, Fluorescence. Opportunistic Infections / genetics. Opportunistic Infections / pathology. Opportunistic Infections / virology. Polymerase Chain Reaction. Sequence Analysis, DNA. Skin / pathology. Skin / virology. Viral Load

  • Genetic Alliance. consumer health - Merkel cell cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1971 Jun 19;1(7712):1253-7 [4104714.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):246-8 [18650846.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Dec;8(4):310-5 [11127923.001]
  • [Cites] Proc Soc Exp Biol Med. 1953 Jun;83(2):414-21 [13064287.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):356-61 [19384948.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):217-24 [18070205.001]
  • [Cites] PLoS Pathog. 2007 May 4;3(5):e64 [17480120.001]
  • [Cites] JAMA. 2005 Sep 28;294(12):1476-80 [16189357.001]
  • [Cites] J Virol. 2007 Apr;81(8):4130-6 [17287263.001]
  • [Cites] J Natl Cancer Inst. 1968 Apr;40(4):867-73 [5646499.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1257-60 [4104715.001]
  • [Cites] Dev Biol Stand. 1998;94:183-90 [9776239.001]
  • [Cites] J Invest Dermatol. 2009 Dec;129(12):2868-74 [19554019.001]
  • [Cites] Proc Soc Exp Biol Med. 1960 Nov;105:420-7 [13774265.001]
  • [Cites] J Am Acad Dermatol. 1999 Aug;41(2 Pt 2):289-91 [10426911.001]
  • [Cites] J Pathol. 2009 May;218(1):48-56 [19291712.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5009-13 [18593898.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):51-6 [17270666.001]
  • [Cites] J Invest Dermatol. 2007 Sep;127(9):2100-3 [17700621.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16272-7 [18812503.001]
  • [Cites] Emerg Infect Dis. 2009 Sep;15(9):1496-8 [19788824.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • (PMID = 19921198.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor
  •  go-up   go-down


11. Kazakov AA, Grishina EE, Tarantul VZ, Gening LV: Effect of human cell malignancy on activity of DNA polymerase iota. Biochemistry (Mosc); 2010 Jul;75(7):905-11
Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of human cell malignancy on activity of DNA polymerase iota.
  • An increased level of mutagenesis, partially caused by imbalanced activities of error prone DNA polymerases, is a key symptom of cell malignancy.
  • To clarify the possible role of incorrect DNA polymerase iota (Pol iota) function in increased frequency of mutations in mammalian cells, the activity of this enzyme in extracts of cells of different mouse organs and human eye (melanoma) and eyelid (basal-cell skin carcinoma) tumor cells was studied.
  • In the presence of Mg2+, the enzyme was active only in cell extracts of mouse testicles and brain, whereas in the presence of Mn2+ the activity of Pol iota was found in all studied normal mouse organs.
  • It was found that in cell extracts of both types of malignant tumors (basal-cell carcinoma and melanoma) Pol iota activity was observed in the presence of either Mn2+ or Mg2+.
  • Manganese ions activated Pol iota in both cases, though to a different extent.
  • In the presence of Mn2+ the Pol iota activity in the basal-cell carcinoma exceeded 2.5-fold that in control cells (benign tumors from the same eyelid region).
  • The distinctive feature of tissue malignancy (in basal-cell carcinoma and in melanoma) was the change in DNA synthesis revealed as Mn2+-activated continuation of DNA synthesis after incorrect incorporation of dG opposite dT in the template by Pol iota.
  • Among cell extracts of different normal mouse organs, only those of testicles exhibited a similar feature.
  • This similarity can be explained by cell division blocking that occurs in all normal cells except in testicles and in malignant cells.
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. DNA-Directed DNA Polymerase / metabolism. Eye Neoplasms / enzymology. Lymphoma, B-Cell, Marginal Zone / enzymology. Melanoma / enzymology
  • [MeSH-minor] Animals. Cell Line, Tumor. Enzyme Activation / drug effects. Enzyme Activators / pharmacology. Humans. Magnesium / pharmacology. Manganese / pharmacology. Mice. Mice, Inbred C57BL. Mutation

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20673215.001).
  • [ISSN] 1608-3040
  • [Journal-full-title] Biochemistry. Biokhimii︠a︡
  • [ISO-abbreviation] Biochemistry Mosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Activators; 42Z2K6ZL8P / Manganese; EC 2.7.7.- / DNA polymerase iota; EC 2.7.7.7 / DNA-Directed DNA Polymerase; I38ZP9992A / Magnesium
  •  go-up   go-down


12. Rodriguez J, Nonaka D, Kuhn E, Reichel M, Rosai J: Combined high-grade basal cell carcinoma and malignant melanoma of the skin ("malignant basomelanocytic tumor"): report of two cases and review of the literature. Am J Dermatopathol; 2005 Aug;27(4):314-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined high-grade basal cell carcinoma and malignant melanoma of the skin ("malignant basomelanocytic tumor"): report of two cases and review of the literature.
  • We describe two cases of a malignant cutaneous neoplasm with combined phenotypical features of high-grade basal cell carcinoma and malignant melanoma.
  • We favor the hypothesis of a tumor with bidirectional keratinocytic and melanocytic differentiation, an exceptionally rare event.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121052.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Chuprov IN: [Basal-cell carcinoma of the skin]. Arkh Patol; 2007 Nov-Dec;69(6):52-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal-cell carcinoma of the skin].
  • The paper represents an overview of updated literature concerning common skin neoplasms.
  • The clinical manifestation of the basal cell carcinoma varies significantly according to the patients age, tumor size, localization and duration of the neoplastic process, histological type of the tumor, including proliferative activity and stromal reactions.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290385.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


14. Kozyreva ON, Konnikov N: The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy.
  • : e14646 Background: Non-melanoma skin cancer (NMSC) is the most common form of human cancer.
  • RESULTS: 43 Caucasian males (range 59- 87 yrs), 37 (87%) had history of NMSC on the face or scalp, 32 (78%) had basal cell carcinoma (BCC), 11 (22%) squamous cell carcinoma (SCC), 100% of patients had multiple (>4) AKs prior to treatment and 23 (75% ) had moderate to severe DH determined by Griffiths scale.
  • Prior to ALA-PDT 74 NMSC's were documented: 40 (54%) BCC and 34 (46%) SCC.
  • 46 NMSC's were documented following ALA-PDT: 22 (48%) BCC and 24 (52%) SCC.
  • Prior to ALA-PDT, the frequency of BCC averaged 2 [IQR 1 to 3, max=4], and the frequency of SCC averaged 1 [IQR 1 to 1, max=3].
  • Following ALA-PDT, the occurrence of BCC averaged 1 [IQR 0 to 1, max=5], and that of SCC averaged 1 [IQR 0 to 2, max= 4].
  • The difference between BCC frequency before and after ALA-PDT treatment shown a significant reduction in BCC incidence (P = 0.0018).
  • No such differences were observed between the frequency of SCC before and after ALA-PDT (P=0.6230) Conclusions: A single ALA-PDT treatment to the face or scalp in high risk patients significantly reduces the incidence of BCC, the incidence of SCC was not reduced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients received E per oral for days 1-21 of a 28 day cycle.
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Booth CM, Li G, Mackillop WJ: The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada. J Clin Oncol; 2009 May 20;27(15_suppl):6505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada.
  • : 6505 Background: Lower SES is known to be associated with worsened cancer survival.
  • Here we evaluate the impact of SES on stage of cancer at diagnosis in Ontario which has universal health insurance.
  • METHODS: All incident cases of breast, colon, rectal, non-small cell lung, cervical and larynx cancer diagnosed in Ontario 2003-2005 were identified using the Ontario Cancer Registry.
  • Stage information is only captured routinely for patients seen at Ontario's 8 Regional Cancer Centers (RCCs).
  • Using a best stage grouping approach, cases were assigned stage based on pathologic TNM if available and clinical TNM otherwise.
  • Using postal code at time of diagnosis cases were assigned to quintiles (Q); Q1 represents the communities where the poorest 20% of the Ontario population resided.
  • RESULTS: Stage at diagnosis was available for 19,239/23,254 (83%) of cases seen at RCCs.
  • Among cases with breast cancer, those in Q1 were less likely to have stage I disease (43 vs 47%, p = 0.004) and more likely to have stage IV disease (5 vs 4%, 0.008) than Q2-5.
  • With lung cancer, cases in Q1 were more likely to have stage I disease compared to Q2-5 (16 vs 13%, p = 0.015).
  • Distribution of stage I and stage IV disease did not differ by SES across other individual diseases.
  • However, for all 6 cancers combined, cases in Q1 were less likely than Q2-5 to have stage I disease (27 vs 30%, p = 0.001) and more likely to have stage IV disease (21 vs 18%, p < 0.0001).
  • We found significant gradients in 3-year overall survival across Q1-Q5 for breast (5% absolute difference in survival, p < 0.001), colon (4%, p = 0.049), and cervical (18%, p = 0.031) cancers.
  • CONCLUSIONS: Despite universal health care, SES remains associated with survival among patients with cancer in Ontario.
  • These data suggest that the difference in outcome is only partially explained by differences in stage at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Maiti B, Kundranda MN, Jin T, Spiro TP, Daw HA: The association of metabolic syndrome with triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of metabolic syndrome with triple-negative breast cancer.
  • : 1038 Background: Metabolic syndrome, a conglomerate of obesity, insulin resistance, hypertriglyceridemia, low HDL (high density lipoprotein), and hypertension is associated with an increased risk of breast cancer.
  • However, no clear association has been shown between the highly aggressive triple-negative breast cancer and metabolic syndrome.
  • METHODS: In a retrospective review we compared triple-negative and non-triple-negative breast cancer cases for the presence of metabolic syndrome by NCEP (National Cholesterol Education Program) or AACE (American Association of Clinical Endocrinologists) definitions.
  • Data on metabolic syndrome criteria, tumor size, grade, lymph node status, and ductal carcinoma in situ (DCIS) were reviewed.
  • RESULTS: The entire cohort of 176 patients (12.5% African-American) with median age 56.5 years (range 26-91 years) comprised of 86 triple-negative cases and 90 non-triple-negative cases.
  • A statistically significant association of triple-negative breast cancer with metabolic syndrome was observed.
  • Contrary to blood glucose, triglyceride, or HDL levels, which independently showed significant association with triple-negative breast cancer, hypertension, or BMI showed no independent association.
  • Additionally, triple-negative tumors displayed a significantly higher histologic grade and relative paucity of ductal carcinoma in situ (DCIS) when compared to the non-triple negative tumors (p < 0.001).
  • CONCLUSIONS: The data suggests that the metabolic syndrome is significantly more prevalent in triple-negative breast cancer patients when compared to the non-triple-negative patients.
  • Additionally, triple-negative breast cancer showed a significantly higher histologic grade and a relative absence of DCIS.
  • Whether the presence of metabolic syndrome preferentially increases the risk of developing triple-negative-breast cancer needs to be elucidated by future prospective studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Gercovich N, Gil Deza E, Russo M, Garcia Gerardi C, Diaz C, Morgenfeld E, Rolnik B, Emina J, Rivarola E, Gercovich FG: Early-stage male breast cancer: A 10-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage male breast cancer: A 10-year experience.
  • : e11630 Introduction: Male breast cancer is very rare, representing only between 0.7% and 1% of all breast cancers, and only half of them are early stage cases.
  • OBJECTIVE: The present study has been designed with the aim of studying retrospectively the clinical onset and evolution of male invasive breast cancer patients (stages I and II) treated at IOHM between 1997 and 2008.
  • METHODS: The records of 3,000 breast cancer cases followed between 1997 and 2008 were searched, looking for male stage I and II breast cancer patients.
  • Tumoral type= Invasive Ductal Carcinoma 12 pt.
  • Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%).
  • Twelve stage I and II male breast cancer patients were identified out of 3000 (0.4%) breast cancer cases diagnosed and followed in the past 10 years at the IOHM.
  • 2. Mastectomy was the surgical procedure in 11 of the 12 cases 3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961181.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR).
  • : 1519 Background: Skin cancers are the most common malignancies in OTR.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Capecitabine, an orally-administered prodrug of 5-FU, in combination with interferon was shown to be effective in the treatment of advanced SCC of the skin.
  • This study was to determine the efficacy of low-dose capecitabine in secondary prevention of the skin cancers in OTR.
  • METHODS: OTR who developed recurrent skin cancers, SCC, and/or basal cell carcinoma (BCC), were given low-dose capecitabine 1g/m2 divided in two daily doses, day 1-14 of 21-day treatment cycle.
  • Skin surveillances were performed by dermatologists every 1 to 3 months.
  • Cumulative incidence rates of SCC, BCC, and AK before and after treatment were scored and statistically compared for each patient with a non-parametric Wilcoxon signed-rank test.
  • Mean incidence rates of SCC, BCC, and AK before treatment were 0.45, 0.05, and 4.99 lesions per month, respectively.
  • Mean incidence rates of SCC, BCC, and AK after treatment were 0.22, 0.04, and 2.80 lesions per month, respectively.
  • The differences in incidence rates of SCC, BCC, and AK before and after treatment were 0.24, 0.02, and 2.08 lesions per month with p value of 0.048, 0.844, and 0.151, respectively.
  • Age and the number of transplants were not significantly related to the change in incidence rates for all skin lesion types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Shapiro G, Kwak E, Baselga J, Rodon J, Scheffold C, Laird AD, Bedell C, Edelman G: Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In preclinical cancer models XL147 is cytostatic or cytoreductive as monotherapy and enhances the efficacy of targeted agents and chemotherapeutics.
  • Drug-related toxicities included grade 3 skin rash (3 pts), grade 3 arterial thrombosis (1 pt), grade 2 transaminase elevation (1 pt), and grade 1 hyperglycemia (4 pts).
  • XL147 reached steady-state plasma concentrations by Day 15-20.
  • XL147 reduced levels of phosphorylated PI3K pathway components in PBMCs, hair, skin, and tumor tissues in an exposure-dependent manner.
  • As of December 2008, 6 pts (3 NSCLC, 1 BCC, 1 NHL, 1 PC) continued on study >6 months including 3 >10 months (NHL, NSCLC, BCC).
  • The most common drug-related toxicity was skin rash.
  • Prolonged stable disease has been observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961287.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Wafa T: Contribution of BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Clin Oncol; 2009 May 20;27(15_suppl):e22191

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
  • : e22191 Background: Hereditary breast cancer accounts for 3-8% of all breast cancers.
  • It was recently estimated that a combination of BRCA1 and BRCA2 genes mutations is responsible for 30% of hereditary breast cancer cases.
  • METHODS: To investigate the prevalence of BRCA1 and BRCA2 gene mutations in breast cancer patients with affected relatives in Tunisia, 36 patients who had at least one first degree relative affected with breast and/or ovarian cancer were analysed.
  • Nineteen percent (7/36) of the familial cases were altered on BRCA1 or BRCA2 genes with deleterious mutations at heterozygous state and 55% (20/36) by mutation with uncertain value (UV) or by single nucleotide polymorphisms (SNPs).
  • CONCLUSIONS: Almost all the cases mutated by deleterious mutations on BRCA1 gene reported a family history of breast and/or ovarian cancer in the index case or in their relatives.
  • On the contrary, patients with an UV mutation or SNPs have no history of ovarian cancer in their corresponding families.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963625.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Wang X, Li Y, Cao X: False-positive diagnosis of breast cancer by diffused optical tomography with ultrasound. J Clin Oncol; 2009 May 20;27(15_suppl):e22085

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive diagnosis of breast cancer by diffused optical tomography with ultrasound.
  • : e22085 Background: Breast cancer is one of the most common cancer in women.
  • Early detection, early diagnosis and early treatment play key role in fighting against breast cancer.
  • It provides dual modality images for early diagnosis of breast cancer.
  • The aim of this study was to evaluate the OPTIMUS system on diagnosis of breast disease.
  • METHODS: OPTIMUS system was applied to 160 breast tumor patients.
  • All patients had received surgical treatment and had definite pathological diagnosis.
  • OPTIMUS system was evaluated as diagnostic tool of breast tumor in this study.
  • RESULTS: There were 42 cases diagnosed as benign breast disease and 118 cases diagnosed as breast cancer by OPTIMUS system.
  • Pathology confirmed 60 cases of benign disease and 100 cases of breast cancer.
  • False positive rate of breast cancer was 30% (18/60).
  • False negative rate of breast cancer was 0% (0/100).
  • The pathology of false positive cases was mild and severe papillomatosis (6/18), non-typical hyperplasia (4/18), chronic inflammation (3/18), fibroadenoma (3/18) and fat necrosis (2/18).
  • Papillomatosis and non-typical hyperplasia are precancerous lesions and often difficult for clinical diagnosis.
  • CONCLUSIONS: OPTIMUS system is a non- invasive and highly effective diagnostic tool for breast disease.
  • Its sensitivity is reached to 100% and specificity is about 70% on the diagnosis of breast cancer.
  • OPTIMUS system could be used as assistant diagnostic tool for breast tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963263.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Gorin MA, Iniesta MD, Douglas JA, Milliron KJ, Merajver SD: Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry. J Clin Oncol; 2009 May 20;27(15_suppl):11040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry.
  • : 11040 Background: Checkpoint kinase 2(CHEK2) is a cell-cycle-checkpoint kinase that phosphorylates p53 and BRCA1 in response to DNA damage.
  • The contribution of CHEK2 mutations to familial cancer has been widely studied in breast cancer.
  • Most notably, the CHEK2*1100delC mutation has been characterized to confer a 2-fold increased risk for breast cancer in carriers.
  • This finding comes from studies performed on Northern and Eastern European populations.
  • In contrast to the work done in Europe, these studies suggest a lower frequency of CHEK2*1100delC mutations in breast cancer families.
  • The aim of this study was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2.
  • Families were characterized by the presence of several cases of breast and/or ovarian cancer and multiple members with other cancers in a single lineage.
  • RESULTS: No CHEK2*1100delC mutations were detected in 115 individuals, including 39 women diagnosed with breast cancer at an early age, 7 women with bilateral cancer, 2 men with breast cancer and 6 women with ovarian cancer, all of whom were negative for mutations in BRCA1/2.The CHEK2 Breast Cancer Consortium previously reported a frequency of 2.3% for the CHEK2*1100delC mutation among breast cancer cases from families with at least 2 cases of breast cancer (or breast and ovarian cancer) in a first- or second-degree relationship.
  • CONCLUSIONS: Our data are consistent with previous reports that suggest a lower frequency of CHEK2*1100delC mutations in North American hereditary breast cancer families without BRCA1/2 mutations and enriched for multiple cancer types.
  • The low frequency of the CHEK2*1100delC in the North American population limits its clinical relevance as a cancer predisposing gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Olsson H, Attner B, Noreen D, Lithman T: Comorbidity prior to diagnosis in patients with common cancer diagnoses. J Clin Oncol; 2009 May 20;27(15_suppl):e22180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity prior to diagnosis in patients with common cancer diagnoses.
  • : e22180 Background: Chronic disease as diabetes, hypertonia and anemia may be associated with cancer risk as well as affect the short term survival of the malignancy.
  • METHODS: Using population based registry data from specialist and primary care in our health care region comorbidity in the form of anemia, hypertonia, diabetes, rheumatoid arthritis, chronic obstructive pulmonary diasease (KOL), and alcohol related diseases for patients with colon-, rectal-, lung-, prostate and breast cancer and survival were studied.
  • Altogether 2047 colon cancer cases, 985 rectal cancer cases, 2017 lung cancer cases, 3578 breast cancer cases and 5106 prostate cancer cases diagnosed 2000-2005 were included.
  • Comorbidity was studied prior to cancer diagnosis and in order to compare with the general population all first comorbidity diagnoses within 90 days were censored.
  • Patients with colon and rectal cancer had a higher prevalence of anemia, and diabetes.
  • Patients with lung cancer had a higher prevalence of anemia, KOL, diabetes, rheumatoid arthritis for both men and women and for men also a higher prevalence of alcohol related diseases.
  • Except for alcohol related diseases in females with breast cancer comorbidity for the above diseases was not significantly elevated for breast or prostate cancer.
  • Survival of the different cancer diagnoses was not significantly related to the comorbidity except for a tendency of worse survival for patients with alcohol related disease.
  • CONCLUSIONS: The prevalence of some common chronic diseases are elevated especially in colon-, rectal and lung cancer patients.
  • The comorbidity does not seem to affect short term survival of the cancer patient except for alcohol related diagnoses.
  • Our study also indicates the necessity to have all levels of care included in the study base of comorbidity and also emphasizes the need to censor time prior to diagnosis when comparing data with the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963595.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Iturbe J Jr, Zwenger A, Lacava JA, Perez Verdera P, Vallejo C, Romero A, Leone JP, Perez J, Maccihavelli M, Leone B: Treatment of early breast cancer (EBC): A long-term follow-up study-GOCS experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of early breast cancer (EBC): A long-term follow-up study-GOCS experience.
  • : e11610 Background: Most cases of breast cancer are diagnosed at early stage of disease, therefore treatment is oriented to increase the relapse-free survival (RFS) and overall survival (OS).
  • RFS was analyzed from the date of initial diagnosis to the date of local or distant recurrence.
  • OS was estimated from the date of initial diagnosis to the last follow-up or date of death.
  • Adjuvant radiation therapy was administered to 73% of pts, whereas adjuvant chemotherapy to 29% and adjuvant hormone therapy to 18.5% of cases.
  • Local recurrence was documented in 37 pts (3.8%) whereas 269 developed metastatic disease (29%).
  • Bilateral breast cancer was seen in 102 cases (10.9%) and 91 pts (9.7%) developed 2nd malignancies.
  • This group of pts continues to have a good prognosis as shown by the OS rate at 5, 10, 15, 20 and 25 years, although high percentage of pts continue to have recurrence and die from breast cancer after 5, 10, 15, 20 and 25 years of follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Hao X, Liu Y, Hui R, Zhang J: Comparison of the sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+ breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+ breast cancer.
  • : e11558 Background: Her2 and PR expression are important indicators for prognosis of breast cancer.
  • METHODS: Collected 3,677 primary breast cancer cases from 2002 to 2004 in Tianjin University Cancer Hospital.
  • All of the cases were confirmed by pathohistological method.
  • With Her2+ breast cancer, 168 patients are PR+/ER- and 211 patients are ER+/PR-.
  • With Her2+ BC, 3-year DFS(disease-free survival rate) of PR+/ER- patients is 94.53%, higher than that of PR-/ER+ ones (91.81%).With Her2- BC, 3-year DFS of PR+/ER- patients is lower than that of PR-/ER+ (p<0.05).
  • 3. Total of 1853 cases with 5-year followed up, and 1297 cases have been given endocrine therapy.
  • CONCLUSIONS: With Her2+ breast cancer, 3-year DFS of PR+/ER- patients is higher than ER+/PR- and also PR+/ER- patients may more sensitive to endocrine therapy than ER+/PR- patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Visram H, Dent SF: Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center. J Clin Oncol; 2009 May 20;27(15_suppl):e11613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center.
  • : e11613 Background: Male breast cancer (BC) comprises approximately 1% of all breast cancer cases, and over 80% of male BC tumours express the estrogen receptor (ER).
  • METHODS: We conducted a retrospective chart review of 24 pts diagnosed with male BC at the Ottawa Regional Cancer Centre from 1986-2003.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Boran C, Parlak AH, Erkol H: Collision tumour of trichofolliculoma and basal cell carcinoma. Australas J Dermatol; 2007 May;48(2):127-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumour of trichofolliculoma and basal cell carcinoma.
  • A 52-year-old woman presented with a 2-year history of a reddish nodule on the right nasolabial sulcus.
  • Histopathological examination revealed that the nodule was composed of trichofolliculoma and basal cell carcinoma.
  • The diagnosis was made as a collision tumour of trichofolliculoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Hair Follicle / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Trichofolliculoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535204.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


29. Lee S, Cnaan RB, Paramanathan N, Davies M, Benger R, Ghabrial R: Subconjunctival "ring" recurrence of Basal cell carcinoma of the globe. Ophthal Plast Reconstr Surg; 2010 Mar-Apr;26(2):117-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subconjunctival "ring" recurrence of Basal cell carcinoma of the globe.
  • Basal cell carcinoma is the most common indication for orbital exenteration.
  • The recurrence rate of BCC removed with microscopically controlled histology sections is up to 6%.
  • The authors describe the recurrence of a lower eyelid BCC resected with microscopic control that did not manifest itself until 15 years later as a subconjunctival lesion, encircling the globe, and without apparent skin involvement.
  • BCC can present in any manner following surgery, and therefore, judicious follow-up is necessary even after microscopically controlled resection.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305512.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


31. Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC: Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol; 2005 Jun;152(6):1108-24
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular aetiology and pathogenesis of basal cell carcinoma.
  • Recent insights into the cell biology of the epidermis and its appendages are transforming our understanding of the pathogenesis of basal cell carcinoma (BCC).
  • The significant progress that has been made warrants a comprehensive review of the molecular and cellular pathology of BCC.
  • The items addressed include environmental and genetic risk factors, the biology of the putative precursor cell(s), and the contribution of aberrations in processes such as apoptosis, cell proliferation, differentiation and signalling to carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Apoptosis. Cell Differentiation. Cell Proliferation. Epidermis / metabolism. Epidermis / pathology. Genetic Predisposition to Disease. Humans. Immunosuppression. Immunotherapy. Risk Factors. Ultraviolet Rays / adverse effects. Virus Diseases / complications. Virus Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2006 Apr;154(4):790-1 [16536838.001]
  • (PMID = 15948971.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 308
  •  go-up   go-down


32. de Zwaan SE, Haass NK: Genetics of basal cell carcinoma. Australas J Dermatol; 2010 May;51(2):81-92; quiz 93-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of basal cell carcinoma.
  • Basal cell carcinoma is the most common human malignancy in populations of European origin, and Australia has the highest incidence of basal cell carcinoma in the world.
  • Great advances in the understanding of the genetics of this cancer have occurred in recent years.
  • Mutations of the patched 1 gene (PTCH1) lead to basal cell carcinoma predisposition in Gorlin syndrome.
  • PTCH1 is part of the hedgehog signalling pathway, and derangements within this pathway are now known to be important in the carcinogenesis of many different cancers including sporadic basal cell carcinoma.
  • The molecular biology of the hedgehog pathway is discussed, and mouse models of basal cell carcinoma based on this pathway are explored.
  • New developments in non-surgical treatment of basal cell carcinoma are based on this knowledge.
  • Other genes of importance to basal cell carcinoma development include the tumour suppressor gene P53 and the melanocortin-1 receptor gene.
  • Evidence of familial aggregation of this cancer is explored and supports the possibility of genetic predisposition to this common malignancy.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / therapy. Disease Models, Animal. Genetic Predisposition to Disease. Hedgehog Proteins / genetics. Humans. Mice. Mutation. Receptor, Melanocortin, Type 1 / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546211.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Receptor, Melanocortin, Type 1; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Protein p53; 0 / patched receptors
  •  go-up   go-down


33. Gambichler T, Orlikov A, Vasa R, Moussa G, Hoffmann K, Stücker M, Altmeyer P, Bechara FG: In vivo optical coherence tomography of basal cell carcinoma. J Dermatol Sci; 2007 Mar;45(3):167-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo optical coherence tomography of basal cell carcinoma.
  • BACKGROUND: Optical coherence tomography (OCT) is a promising non-invasive imaging technique that has not systematically been studied in skin cancer such as basal cell carcinoma (BCC).
  • OBJECTIVE: We aimed, first, to describe the in vivo histologic features of BCC by using OCT, and second, to find out whether it is possible to differentiate BCC subtypes by means of OCT.
  • METHODS: Prior to the excision, the BCCs (n=43) as well as adjacent non-lesional skin sites were assessed by OCT in vivo.
  • RESULTS: Compared to non-lesional skin, a loss of normal skin architecture and disarrangement of the epidermis and upper dermis was observed in the OCT images of BCCs.
  • With regard to the aforementioned OCT features, no statistically significant (P<0.05) difference was found between nodular, multifocal superficial, and infiltrative BCCs, respectively.
  • CONCLUSIONS: OCT is capable to visualize altered skin architecture and histopathological correlates of BCC.
  • However, there is not at this time sufficient data supporting the clinical use of OCT for the differentiation of BCC subtypes.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Tomography, Optical Coherence
  • [MeSH-minor] Aged. Dermis / pathology. Diagnosis, Differential. Epidermis / pathology. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17215110.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Vogler N, Meyer T, Akimov D, Latka I, Krafft C, Bendsoe N, Svanberg K, Dietzek B, Popp J: Multimodal imaging to study the morphochemistry of basal cell carcinoma. J Biophotonics; 2010 Oct;3(10-11):728-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal imaging to study the morphochemistry of basal cell carcinoma.
  • Basal cell carcinoma is the most abundant malignant neoplasm in humans, the pathology of which is characterized by an abnormal proliferation of basal cells.
  • Basal cell carcinoma can show a variety of different morphologies, which are based on different cellular biology.
  • Furthermore, the carcinoma often grows invisibly to the eye imbedded in the surrounding skin.
  • Therefore, in some cases its clinical detection is challenging.
  • Thus, our work aims at establishing an unsupervised tissue classification method based on multimodal imaging and the application of chemometrics to discriminate basal cell carcinoma from non-diseased tissue.
  • A case study applying multimodal imaging to ex-vivo sections of basal cell carcinoma is presented.
  • In doing so, we apply a combination of various linear and non-linear imaging modalities, i.e. fluorescence, Raman and second-harmonic generation microscopy, to study the morphochemistry of basal cell carcinoma.
  • The joint information content obtained by such multimodal approach in studying various aspects of the malignant tissue alterations associated with basal cell carcinoma is discussed.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Molecular Imaging / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20648521.001).
  • [ISSN] 1864-0648
  • [Journal-full-title] Journal of biophotonics
  • [ISO-abbreviation] J Biophotonics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Kleydman Y, Manolidis S, Ratner D: Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol; 2009 Jun;60(6):1045-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with intracranial invasion.
  • The risk of invasion and destruction of cranium, underlying dura, and cranial nerves by basal cell carcinoma (BCC) is extremely low, with an estimated incidence of 0.03%.
  • Intracranial BCC invasion by direct extension is rare, and orbital spread from a nasal lesion has not been reported in the literature.
  • We describe a case of intracranial invasion of a multiply recurrent nasal BCC, which caused progressive bilateral blindness from optic nerve compression, with spinal canal involvement causing subsequent lower extremity weakness and paralysis.
  • This case underscores the importance of early and appropriate treatment of high risk BCC, and aggressive treatment of recurrent lesions as early as possible.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Orbit / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Blindness / etiology. Female. Humans. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467376.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Paavilainen V, Tuominen J, Pukkala E, Saari KM: Basal cell carcinoma of the eyelid in Finland during 1953-97. Acta Ophthalmol Scand; 2005 Apr;83(2):215-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelid in Finland during 1953-97.
  • PURPOSE: To study the incidence of basal cell carcinoma (BCC) of the eyelid in Finland.
  • METHODS: We studied 6241 cases of BCC of the eyelid reported to the nationwide Finnish Cancer Registry during 1953-97.
  • RESULTS: The incidence rates of BCC of the eyelid varied between 0.7 and 3.0 per 100 000 person-years in men and between 0.5 and 2.8 per 100 000 person-years in women during the study period.
  • The age-adjusted incidence rates of BCC of the eyelid increased during 1953-87 (p < 0.0001).
  • The incidence of BCC of the eyelid rose significantly with age.
  • There were no significant differences in standardized incidence ratios (SIRs) for BCC of the eyelid between different social class and occupation categories.
  • CONCLUSION: Age-adjusted incidence rates showed that BCC of the eyelid was more than twice as frequent during 1978-97 than before 1968.
  • Ageing may partly explain the increased incidence of BCC of the eyelid, whereas there were no differences in the SIRs for BCC of the eyelid between different social class and occupation categories in Finland.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Eyelid Neoplasms / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15799736.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


37. Uhara H, Hayashi K, Koga H, Saida T: Multiple hypersonographic spots in basal cell carcinoma. Dermatol Surg; 2007 Oct;33(10):1215-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple hypersonographic spots in basal cell carcinoma.
  • BACKGROUND: High-frequency ultrasound is a useful method to obtain preoperative information regarding extension of basal cell carcinoma.
  • Its contribution to diagnosis is generally limited, however.
  • Recently, we observed hypersonographic spots in some cases of basal cell carcinoma.
  • OBJECTIVE: The present study was performed to determine the diagnostic value of this finding in this type of tumor.
  • MATERIALS AND METHODS: We conducted a retrospective study of archived sonographic images with a 30- or 15-MHz scanner and histology specimens of a total of 85 lesions, consisting of 29 basal cell carcinomas and 56 melanomas.
  • RESULTS: The findings were classified into four patterns as follows: Type A, multiple (more than five spots/lesion) hypersonographic spots (14 cases, 48%); Type B, sparse (3-5 spots/lesion) hypersonographic spots (7 cases, 24%); Type C, multiple moderate sonographic spots (3 cases, 10%); and Type D, sparse moderate sonographic spots (5 cases, 17%).
  • Histopathologically, these hypersonographic spots in BCCs seemed to correspond to calcification, horn cysts, or clusters of apoptotic cells in the centers of nests of basal cell carcinoma.
  • CONCLUSION: Multiple hypersonographic spots might become a useful finding for differential diagnosis between basal cell carcinoma and melanoma.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Melanoma / ultrasonography. Skin Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Basal Cell Carcinoma, Multiple.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903154.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Potier A, Avenel Audran M, Belperron P, Briand E, Croue A, Verret JL: [Basal cell carcinoma of the first toenail]. Ann Dermatol Venereol; 2007 Oct;134(10 Pt 1):757-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell carcinoma of the first toenail].
  • [Transliterated title] Carcinome basocellulaire de l'appareil unguéal de l'hallux.
  • BACKGROUND: Basal cell carcinoma is a very common form of skin cancer but its occurrence on the toenail unit is very rare.
  • We report such a case of basal cell carcinoma localized on the proximal nail fold of the right hallux.
  • CASE REPORT: A 67-year-old woman had a 7-year history of a non-healing ulcer on the proximal nail fold of the right hallux after antibiotics and treatment of her onychomycosis.
  • Bowen's disease and squamous cell carcinoma were suspected.
  • Histopathologic examination of a biopsy specimen revealed infiltrative basal cell carcinoma.
  • The lesion was surgically excised with a 0.5 cm margin and the defect was repaired by full-thickness skin graft with good functional and cosmetic results.
  • DISCUSSION: Basal cell carcinoma is the most common skin cancer but its localization on fingers, toes and nail units is very rare.
  • Only six cases of basal cell carcinoma on the toe nail unit have been reported to date in the literature.
  • Our case emphasizes the value of biopsy for all nail unit lesions of atypical appearance, course or therapeutic response.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nail Diseases / pathology. Nails. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978714.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


39. Cicchi R, Massi D, Sestini S, Carli P, De Giorgi V, Lotti T, Pavone FS: Multidimensional non-linear laser imaging of Basal Cell Carcinoma. Opt Express; 2007 Aug 6;15(16):10135-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidimensional non-linear laser imaging of Basal Cell Carcinoma.
  • We have used a multidimensional non-linear laser imaging approach to visualize ex-vivo samples of basal cell carcinoma (BCC).
  • A combination of several non-linear laser imaging techniques involving fluorescence lifetime, multispectral two-photon and second-harmonic generation imaging has been used to image different skin layers.
  • This approach has elucidated some morphological (supported by histopathological images), biochemical, and physiochemical differences of the healthy samples with respect to BCC ones.
  • In particular, in comparison with normal skin, BCC showed a blue-shifted fluorescence emission, a higher fluorescence response at 800 nm excitation wavelength and a slightly longer mean fluorescence lifetime.
  • The results obtained provide further support for in-vivo non-invasive imaging of Basal Cell Carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547362.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Gulia A, Altamura D, De Trane S, Micantonio T, Fargnoli MC, Peris K: Pigmented reticular structures in basal cell carcinoma and collision tumours. Br J Dermatol; 2010 Feb 1;162(2):442-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented reticular structures in basal cell carcinoma and collision tumours.
  • BACKGROUND: The dermatoscopic diagnosis of basal cell carcinoma (BCC) is based on well-known specific criteria.
  • Despite the fact that a pigment network is considered a negative feature for the diagnosis of BCC, its detection in a BCC context has been reported in 2.8% of cases.
  • OBJECTIVES: To determine whether pigment networks or network-like structures might represent a pitfall for the correct diagnosis of BCC.
  • METHODS: Dermatoscopic images of 412 histopathologically proven BCCs were analysed retrospectively.
  • RESULTS: Pigment network or network-like structures were detected in 14 of 412 (3.4%) BCCs.
  • Nine of 14 BCCs presented a typical pigment network, due to the association of a BCC lesion with a naevus, solar lentigo or actinic keratosis; two BCCs located on the face showed a pseudonetwork, and three of 14 lesions displayed a network-like structure characterized by light-brown irregularly meshed short linear structures, histopathologically related to a hyperpigmentation of the basal layer of the epidermis.
  • CONCLUSIONS: The presence of a pigment network in the context of a BCC is uncommon, and it usually reflects the association of BCC with a solar lentigo, naevus or a specific location of the lesion on photodamaged skin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Dermoscopy / methods. Melanins. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Retrospective Studies. Skin Pigmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754866.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


41. Griffin JR, Cohen PR, Tschen JA, Mullans EA, Schulze KE, Martinelli PT, Nelson BR: Basal cell carcinoma in childhood: case report and literature review. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S97-102
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in childhood: case report and literature review.
  • Childhood onset basal cell carcinoma is uncommon.
  • In addition to occurring in children with albinism, Bazex syndrome, basal cell carcinoma nevus syndrome, nevus sebaceus, radiotherapy-treated cancers, solid organ transplants, and xeroderma pigmentosum, childhood onset basal cell carcinoma has also occurred, albeit less commonly, de novo.
  • We describe a boy with idiopathic childhood onset basal cell carcinoma.
  • Previously published children with de novo basal cell carcinoma were collected from computerized medical literature search (PubMed) and citations from earlier reports.
  • To our knowledge, childhood onset idiopathic basal cell carcinoma has been observed in a total of 107 children, including our patient.
  • Basal cell carcinoma in children may be associated with prior sun exposure.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938034.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


42. Telfer NR, Colver GB, Morton CA, British Association of Dermatologists: Guidelines for the management of basal cell carcinoma. Br J Dermatol; 2008 Jul;159(1):35-48
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the management of basal cell carcinoma.
  • This article represents a planned regular updating of the previous British Association of Dermatologists guidelines for the management of basal cell carcinoma.
  • These guidelines present evidence-based guidance for treatment, with identification of the strength of evidence available at the time of preparation of the guidelines, and a brief overview of epidemiological aspects, diagnosis and investigation.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18593385.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Review
  • [Publication-country] England
  • [Number-of-references] 181
  •  go-up   go-down


43. Rodriguez C, Barriuso V, Chan LS: Extensive basal cell carcinoma with probable bone metastasis. Cutis; 2007 Jul;80(1):60-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive basal cell carcinoma with probable bone metastasis.
  • Metastasis of basal cell carcinoma (BCC) rarely occurs.
  • Few cases have been reported in the literature; those cases reported generally resulted from chronic, extensive, recurrent lesions on the head or neck.
  • With regard to bone metastases, several case reports have demonstrated similar clinical features indicative of osseous involvement.
  • We present a case report of a patient with an extensive BCC with histologic documentation and probable bone metastasis of BCC.
  • Clinical and radiographic features of this case were consistent with previously reported patients.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725067.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


44. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, Sotiropoulou PA, Blanpain C: Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol; 2010 Mar;12(3):299-305
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the cell lineage at the origin of basal cell carcinoma.
  • For most types of cancers, the cell at the origin of tumour initiation is still unknown.
  • Here, we used mouse genetics to identify cells at the origin of basal cell carcinoma (BCC), which is one of the most frequently occurring types of cancer in humans, and can result from the activation of the Hedgehog signalling pathway.
  • Using mice conditionally expressing constitutively active Smoothened mutant (SmoM2), we activated Hedgehog signalling in different cellular compartments of the skin epidermis and determined in which compartments Hedgehog activation induces BCC formation.
  • Activation of SmoM2 in hair follicle bulge stem cells and their transient amplifying progenies did not induce cancer formation, demonstrating that BCC does not originate from bulge stem cells, as previously thought.
  • Using clonal analysis, we found that BCC arises from long-term resident progenitor cells of the interfollicular epidermis and the upper infundibulum.
  • Our studies uncover the cells at the origin of BCC in mice and demonstrate that expression of differentiation markers in tumour cells is not necessarily predictive of the cancer initiating cells.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cell Lineage. Epidermis / pathology
  • [MeSH-minor] Animals. Bacterial Proteins / genetics. Bacterial Proteins / metabolism. Cadherins / metabolism. Cell Count. Cell Differentiation. Clone Cells / metabolism. Clone Cells / pathology. Ear, External / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Genes, Reporter / genetics. Hair Follicle / metabolism. Hair Follicle / pathology. Hedgehog Proteins / genetics. Integrases / genetics. Integrin beta4 / metabolism. Keratin-10 / metabolism. Keratin-14 / genetics. Keratin-15 / genetics. Keratin-15 / metabolism. Keratin-19 / genetics. Kruppel-Like Transcription Factors / metabolism. Luminescent Proteins / genetics. Luminescent Proteins / metabolism. Mice. Mice, Inbred Strains. Mice, Transgenic. Models, Biological. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Proteins / genetics. Proteins / metabolism. RNA, Untranslated. Receptors, Cell Surface / metabolism. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Skin / metabolism. Skin / pathology. Tail / pathology

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cell Stem Cell. 2010 Apr 2;6(4):292-4 [20362530.001]
  • (PMID = 20154679.001).
  • [ISSN] 1476-4679
  • [Journal-full-title] Nature cell biology
  • [ISO-abbreviation] Nat. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cadherins; 0 / Gt(ROSA)26Sor non-coding RNA, mouse; 0 / Hedgehog Proteins; 0 / Integrin beta4; 0 / Keratin-14; 0 / Keratin-15; 0 / Keratin-19; 0 / Krt1-10 protein, mouse; 0 / Krt1-14 protein, mouse; 0 / Krt1-15 protein, mouse; 0 / Kruppel-Like Transcription Factors; 0 / Luminescent Proteins; 0 / Proteins; 0 / RNA, Untranslated; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Shh protein, mouse; 0 / Smo protein, mouse; 0 / patched receptors; 0 / yellow fluorescent protein, Bacteria; 147785-83-9 / Keratin-10; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


45. Cheretis C, Dietrich F, Chatzistamou I, Politi K, Angelidou E, Kiaris H, Mkrtchian S, Koutselini H: Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma. Am J Dermatopathol; 2006 Oct;28(5):410-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma.
  • To test if ERp29 is associated with the pathogenesis of skin cancer, in the present study we have assessed the expression of ERp29 in basal-cell carcinoma of the skin.
  • A bank of 104 basal skin carcinoma, including 50 nodular, 29 infiltrating, 15 superficial, 7 sclerosing, 2 fibroepithelial, and 1 pigmented cell carcinoma, were assessed by immunohistochemistry for ERp29 expression.
  • Thirty-nine (37.5%) of the samples tested expressed ERp29 with the infiltrating carcinomas displaying more intense (++,+++) immunoreactivity (6/29, P < 0.05) and the superficial carcinomas exhibiting the less intense anti-ERp29 staining (1/15, P < 0.05).
  • Collectively our results suggest that ERp29 is expressed in a subset of basal-cell carcinoma of the skin with the infiltrating carcinomas exhibiting the highest incidence of immunopositivity.
  • The role of ERp29 in the pathogenesis of the disease and its potential diagnostic value should be explored in future investigations.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Endoplasmic Reticulum / secretion. Heat-Shock Proteins / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17012915.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ERP29 protein, human; 0 / Heat-Shock Proteins
  •  go-up   go-down


46. Weyers W, Hörster S, Diaz-Cascajo C: Tumor of follicular infundibulum is Basal cell carcinoma. Am J Dermatopathol; 2009 Oct;31(7):634-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of follicular infundibulum is Basal cell carcinoma.
  • Tumor of follicular infundibulum (TFI) is currently thought to be a benign epithelial neoplasm with follicular differentiation.
  • It is encountered commonly in association with basal cell carcinoma (BCC), often as an incidental finding.
  • We reexamined 24 cases of TFI and noted, often only focally, many changes typical of BCC, including palisading of cells at the periphery of aggregations, germinative cells, follicular germs in the absence of a follicular papilla, crowding of cells, individual necrotic neoplastic cells, fibromucinous stroma, and clefts between aggregations of neoplastic cells and stroma.
  • Five cases were associated with BCC, and 2 of them showed obvious continuity between both types of lesions.
  • Moreover, we observed recurrences of what seemed to be a completely removed BCC in which tiny columns of cells typical of TFI were present in surgical margins.
  • Those findings prompted us to conclude that TFI may be one of many manifestations of BCC rather than a differential diagnosis of it.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652582.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Alcalay J, Ben-Amitai D, Alkalay R: Idiopathic basal cell carcinoma in children. J Drugs Dermatol; 2008 May;7(5):479-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic basal cell carcinoma in children.
  • Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in humans, and is the most common malignant neoplasm among adults in the US.
  • Childhood onset of BCC is rare and usually associated with genetic disorders such as basal cell nevus syndrome, Bazex syndrome, albinism, and xeroderma pigmentosum or due to radiation therapy.
  • A girl with idiopathic onset of BCC who was treated with Mohs micrographic surgery is reported.
  • A total of 108 children including this patient were reported with idiopathic de novo BCC.
  • Basal cell carcinoma in children is probably the result of genetic background and intense ultraviolet radiation exposure.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505143.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Gerritsen MJ, De Rie MA, Beljaards RC, Thissen MR, Kuipers MV: Survey among patients with basal cell carcinoma in The Netherlands. J Dermatolog Treat; 2009;20(4):213-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey among patients with basal cell carcinoma in The Netherlands.
  • This paper describes the findings of a survey distributed among Dutch patients with basal cell carcinoma (BCC).
  • The questionnaire comprised a list of questions related to demographic characteristics, features of BCC, reason for consulting a dermatologist, anxiety, type of treatment and the satisfaction with this treatment and desired benefits of treatment.
  • Half of the patient group had already previously experienced a BCC.
  • Most patients (52%) indicated that the diagnosis 'skin cancer' frightened them, but that they knew it could be treated.
  • Accordingly, most patients (70%) indicated that BCC had no or hardly any influence on their quality of life.
  • From the patient's perspective, efficacy, low recurrence rate and no or minor scarring are important features of a BCC treatment.
  • The number of BCC patients is growing, which will lead to a definite burden for dermatologists in the near future.
  • [MeSH-major] Carcinoma, Basal Cell. Patient Satisfaction / statistics & numerical data. Skin Neoplasms. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125362.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C: CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol; 2006 Feb;33(2):123-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in trichoepithelioma and basal cell carcinoma.
  • BACKGROUND: Trichoepithelioma (TE) is a benign neoplasm that shares both clinical and histologic features with basal cell carcinoma (BCC).
  • METHODS: CD10 protein immunohistochemistry was performed on paraffin-embedded biopsies of 13 TE and 23 BCC diagnosed by routine microscopy.
  • Cases were analyzed for pattern of CD10 expression by tumor cells and surrounding stroma.
  • Of these, eight cases also demonstrated positivity of the papilla, and two also showed positivity of the basaloid cells.
  • On the other hand, expression of CD10 by basaloid cells was identified in 20 (87%) cases of BCC.
  • Stromal positivity was also identified in three cases of BCC.
  • Condensation of CD10-positive stromal cells around basaloid nests was statistically significant in differentiating TE from BCC (p < 0.0001).
  • Conversely, CD10-positive basaloid cells were seen predominantly in BCC (p < 0.0001).
  • CONCLUSIONS: This study demonstrates a statistically significant difference in CD10 staining pattern between TE and BCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Neoplasms, Basal Cell / metabolism. Neprilysin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420307.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


50. Newman JC, Leffell DJ: Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg; 2007 Aug;33(8):957-64; discussion 965
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma.
  • BACKGROUND: The clinical relevance of the anatomic distribution of basal cell carcinoma is not completely understood.
  • Embryonic fusion planes--the regions of mesenchymal migration and fusion of the five primordial facial processes during the 5th to 10th weeks of human development--have been implicated in the pathogenesis of basal cell carcinoma.
  • OBJECTIVE: This study sought to examine the predilection of midfacial basal cell carcinoma for cutaneous anatomical sites correlated to embryonic fusion planes.
  • METHODS AND MATERIALS: Using archived digital images and a detailed anatomic diagram, cases of basal cell carcinoma were coded according to their specific location and were aggregated into two anatomic domains according to their correlation to embryonic fusion planes.
  • RESULTS: Of the 1,457 cases examined, 859 were located in the midface.
  • CONCLUSIONS: Although there is no consensus about the importance of anatomic location in the pathogenesis of basal cell carcinoma, these data indicate that, after adjusting for surface area, basal cell carcinoma was more than four times more likely to occur on an embryonic fusion plane than on other regions of the midface.
  • These data support the possibility of an embryologic role for the pathogenesis of basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / embryology. Carcinoma, Basal Cell / pathology. Facial Neoplasms / embryology. Facial Neoplasms / pathology. Skin Neoplasms / embryology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Jun;34(6):851-3; author reply 853 [18384370.001]
  • (PMID = 17661939.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Smullen MJ, Bertler DE: Basal cell carcinoma of the sole: possible association with the shoe-fitting fluoroscope. WMJ; 2007 Aug;106(5):275-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the sole: possible association with the shoe-fitting fluoroscope.
  • Basal cell carcinoma of the sole is very rare.
  • This report describes an occurrence in which a basal cell carcinoma may have developed in relation to radiation exposure from a shoe-fitting fluoroscope.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Fluoroscopy / adverse effects. Foot Diseases / etiology. Neoplasms, Radiation-Induced. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874675.001).
  • [ISSN] 1098-1861
  • [Journal-full-title] WMJ : official publication of the State Medical Society of Wisconsin
  • [ISO-abbreviation] WMJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Konstantinidis A, Ghosh Y, Snead D, Ahluwalia H: Eyelid basal cell carcinoma with osteosarcomatous changes. Ophthal Plast Reconstr Surg; 2008 Jul-Aug;24(4):322-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma with osteosarcomatous changes.
  • Histopathology of the lesion supported the diagnosis of basal cell carcinoma with osteosarcomatous changes.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Aged, 80 and over. Blepharoplasty. Cell Differentiation. Female. Humans. Reconstructive Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645447.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Mostafa WZ, Mahfouz SM, Bosseila M, Sobhi RM, El-Nabarawy E: An immunohistochemical study of laminin in basal cell carcinoma. J Cutan Pathol; 2010 Jan;37(1):68-74
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of laminin in basal cell carcinoma.
  • BACKGROUND: Laminins are components of the extracellular matrix that mediate cell adhesion, growth, migration, proliferation and differentiation.
  • Basement membrane (BM) laminins, in particular, may play a role in enhancing carcinoma cell motility.
  • AIM: To evaluate the distribution pattern of laminin in basal cell carcinoma (BCC), as regards the basement membrane, cellular cytoplasm, peritumoral lacunae and surface epithelium and to correlate laminin distribution with different variants of BCC.
  • PATIENTS AND METHODS: Skin biopsy specimens were obtained from 21 BCC patients for routine histopathological and immunohistochemical study.
  • Code No: MO638, which reacts with the terminal globular domain of the α5 chain) RESULTS: The majority of BCC cases showed patchy cytoplasmic distribution of laminin.
  • The BM expression of laminin, in most cases, was well defined, fine and linear with irregular areas of thickening.
  • CONCLUSION: Cytoplasmic and basement membrane laminin is important in the pathogenesis and invasion of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Laminin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy. Child. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Skin Aging. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 19615022.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin
  •  go-up   go-down


54. So PL, Tang JY, Epstein EH: Novel investigational drugs for basal cell carcinoma. Expert Opin Investig Drugs; 2010 Sep;19(9):1099-112
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel investigational drugs for basal cell carcinoma.
  • IMPORTANCE OF THE FIELD: In the United States, the annual incidence of basal cell carcinoma (BCC) is close to 1 million.
  • Ultraviolet radiation exposure is the main risk factor; however, the availability of ever more potent sunscreens and education have not prevented the rise in BCC incidence.
  • AREAS COVERED IN THIS REVIEW: This article summarizes our current understanding of the etiology and molecular mechanisms of BCC tumorigenesis and discusses the preclinical and clinical studies to identify agents with anti-BCC efficacy.
  • WHAT THE READER WILL GAIN: The discovery that hyperactive Hh pathway signaling causes several cancers, including BCC, has spawned the development of many pharmacologic inhibitors of Hh signaling.
  • Early clinical testing of the most advanced, GDC-0449, demonstrated impressive efficacy in patients with advanced BCC.
  • Other promising anti-BCC chemopreventive strategies include drugs that are already FDA-approved for treating other diseases.
  • TAKE HOME MESSAGE: Preclinical and clinical trials with pre-existing FDA-approved drugs suggest novel uses for BCC chemoprevention and treatment.
  • Also, new chemical entities that inhibit the Hh pathway show promise, and in combination with other drugs may provide a nonsurgical cure for this most common cancer.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Drugs, Investigational / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10171-8 [17047082.001]
  • [Cites] PLoS Biol. 2006 Jul;4(8):e232 [16895439.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1770(3):467-77 [16963187.001]
  • [Cites] Mutat Res. 2007 Apr 1;617(1-2):138-46 [17307204.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3483-91 [17409458.001]
  • [Cites] J Am Acad Dermatol. 2007 May;56(5):781-5 [17261341.001]
  • [Cites] J Nutr Biochem. 2007 May;18(5):287-96 [17049833.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60 [17494766.001]
  • [Cites] Cancer Lett. 2007 Aug 8;253(1):53-9 [17321042.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2185-8 [17695502.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Nov 1;224(3):249-56 [17234230.001]
  • [Cites] Med Hypotheses. 2008;70(1):202-3 [17870251.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):249-60 [18328428.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1248-55 [18403589.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1275-84 [18483315.001]
  • [Cites] Clin Interv Aging. 2008;3(1):71-6 [18488880.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2022-32 [18645012.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2725-35 [18790753.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] Nutr Rev. 2008 Oct;66(10 Suppl 2):S116-24 [18844838.001]
  • [Cites] J Med Chem. 2008 Nov 13;51(21):6646-9 [18842035.001]
  • [Cites] Dev Cell. 2008 Dec;15(6):801-12 [19081070.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):9-18 [19124815.001]
  • [Cites] Oncol Rep. 2009 Mar;21(3):689-92 [19212627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2623-8 [19196978.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3196-201 [19218434.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(13):2321-4 [19222062.001]
  • [Cites] Exp Oncol. 2009 Mar;31(1):9-15 [19300410.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):310-21 [19336730.001]
  • [Cites] J Am Acad Dermatol. 2009 Jul;61(1):66-72 [19464071.001]
  • [Cites] Org Lett. 2009 Jul 2;11(13):2824-7 [19552464.001]
  • [Cites] Mar Drugs. 2009;7(2):153-65 [19597578.001]
  • [Cites] Bioorg Med Chem. 2009 Jul 15;17(14):4943-54 [19541490.001]
  • [Cites] J Med Chem. 2009 Jul 23;52(14):4400-18 [19522463.001]
  • [Cites] Expert Opin Ther Pat. 2009 Aug;19(8):1039-56 [19505195.001]
  • [Cites] PLoS One. 2009;4(8):e6593 [19672316.001]
  • [Cites] Cardiovasc Drugs Ther. 2009 Aug;23(4):261-2 [19618258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14132-7 [19666565.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1055-61 [19701205.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:78-84 [19775361.001]
  • [Cites] J Dermatol Sci. 2009 Nov;56(2):76-81 [19781914.001]
  • [Cites] Science. 2009 Oct 23;326(5952):572-4 [19726788.001]
  • [Cites] J Dermatolog Treat. 2009;20(6):328-35 [19954388.001]
  • [Cites] Mol Biosyst. 2010 Jan;6(1):44-54 [20024066.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):8-11 [20051367.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):35-47 [20051371.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Feb;3(2):132-5 [20103730.001]
  • [Cites] Cancer Cell. 2010 Apr 13;17(4):388-99 [20385363.001]
  • [Cites] Anticancer Res. 2010 Mar;30(3):777-83 [20392996.001]
  • [Cites] J Invest Dermatol. 2010 May;130(5):1438-43 [20043012.001]
  • [Cites] Med Res Rev. 2011 Mar;31(2):161-201 [19967720.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Aug;15(8):868-71 [2754091.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12125-8 [8647801.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Mol Carcinog. 2009 May;48(5):408-19 [18781608.001]
  • [Cites] PLoS One. 2009;4(5):e5592 [19440351.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1966-7 [19411834.001]
  • [Cites] Trends Pharmacol Sci. 2009 Jun;30(6):303-12 [19443052.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3438-43 [10725363.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 2;280(4):1042-7 [11162632.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2001 Nov-Dec;14(6):358-62 [11598435.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Oncogene. 2001 Nov 22;20(53):7770-8 [11753655.001]
  • [Cites] Dermatol Surg. 2001 Dec;27(12):1035-8 [11849266.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4773-80 [12183437.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6 [12391318.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):269-73 [12423433.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):151-6 [12582025.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21 [12679522.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3933-8 [14999099.001]
  • [Cites] J Clin Invest. 2004 Mar;113(6):867-75 [15067319.001]
  • [Cites] Skin Pharmacol Physiol. 2004 May-Jun;17(3):111-8 [15087589.001]
  • [Cites] J Invest Dermatol. 2004 Apr;122(4):1037-41 [15102095.001]
  • [Cites] Eur J Dermatol. 2004 Mar-Apr;14(2):96-102 [15196999.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5350-9 [15094780.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):148-56 [15270884.001]
  • [Cites] Cancer Lett. 2004 Nov 8;215(1):1-20 [15374627.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Hum Mol Genet. 2004 Nov 1;13(21):2595-606 [15367491.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] Int J Dermatol. 1987 Nov;26(9):606-9 [3443534.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Lett. 1997 Jun 24;116(2):197-203 [9215864.001]
  • [Cites] J Am Acad Dermatol. 1997 Aug;37(2 Pt 3):S12-7 [9270551.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] J Invest Dermatol. 1998 Oct;111(4):656-61 [9764849.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):833-6 [9989836.001]
  • [Cites] Exp Cell Res. 2004 Dec 10;301(2):189-200 [15530855.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):43-51 [15656799.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Eur J Cancer Prev. 2005 Oct;14(5):473-6 [16175052.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):1143-51 [16528365.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] Int J Dermatol. 2006 May;45(5):489-98 [16700779.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):933-46; quiz 947-50 [16713450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8408-13 [16707575.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:197-204 [16869754.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):742-50 [16881970.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1917-22 [16679309.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9731-5 [17018632.001]
  • (PMID = 20662553.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR056736; United States / NIAMS NIH HHS / AR / K23 AR056736-03
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Drugs, Investigational; 0 / Hedgehog Proteins
  • [Other-IDs] NLM/ NIHMS298539; NLM/ PMC3775578
  •  go-up   go-down


55. Katircioglu YA, Yildiz EH, Kocaoglu FA, Ozer E, Ornek F, Duman S: Basal cell carcinoma in lacrimal sac. Orbit; 2007 Dec;26(4):303-7
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in lacrimal sac.
  • Biopsy revealed islets of classical basal cell carcinoma with peripheral formation of palisades within a hyperemic stroma.
  • As far as the authors know, this is the first case of basal cell carcinoma in the lacrimal sac reported in the literature.
  • [MeSH-major] Eye Neoplasms / diagnosis. Lacrimal Apparatus Diseases / diagnosis
  • [MeSH-minor] Biopsy. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097974.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Caresana G, Giardini R: Dermoscopy-guided surgery in basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Dec;24(12):1395-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy-guided surgery in basal cell carcinoma.
  • BACKGROUND: In basal cell carcinoma (BCC), excision margins between 3 and 10 mm, according to site, size, borders, previous treatment and histology, can allow for radical excision in at least 95% of cases.
  • OBJECTIVE: The objective was to ascertain whether dermoscopy can detect more accurately the lateral borders in BCCs than clinical examination alone, and allow us to obtain radical excision in more than 95% of cases with only 2-mm excision margins.
  • METHODS: A prospective study was performed of 200 consecutive BCCs of the head and neck removed with 2-mm dermoscopically detected excision margins.
  • Morpheaform BCC, deeply recurrent BCC, BCC in Gorlin-Goltz syndrome, BCC located in sites not accessible through dermoscopy and superficial multifocal BCC were excluded.
  • All cases of excised BCC were submitted to a uniform method of histological examination of the whole specimen with serial parallel sections at 2-mm intervals.
  • RESULTS: In only three cases did surgical excision with 2-mm margins prove to be inadequate; in the remaining 197 cases, the excision margins were tumour-free.
  • The comparison of clinical and dermoscopic extension measurement showed concordance in 131 cases (65.5%).
  • In 69 cases (34.5%), dermoscopic evaluation showed a larger peripheral extension.
  • CONCLUSIONS: These results indicate that 2-mm dermoscopically detected excision margins can achieve histologically confirmed complete excisions in 98.5% of cases.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Dermoscopy. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20384678.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972311.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Krahl D, Sellheyer K: Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol; 2007 Oct;34(10):782-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma.
  • It is diagnostically highly reliable in the differentiation between basal cell carcinoma and cutaneous squamous cell carcinoma.
  • In this study, we report its application in the differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and basal cell carcinoma.
  • METHODS: Biopsy samples from 28 sclerosing and infiltrating basal cell carcinomas, 13 microcystic adnexal carcinomas and 16 desmoplastic trichoepitheliomas were examined after immunohistochemical staining with Ber-EP4.
  • RESULTS: Ber-EP4 did not label any of the microcystic adnexal carcinomas, whereas all 28 basal cell carcinomas were Ber-EP4 positive.
  • Only one basal cell carcinoma was weakly positive.
  • Twelve of the 16 desmoplastic trichoepitheliomas were immunoreactive with Ber-EP4 and the staining was more variable than those of basal cell carcinomas.
  • CONCLUSIONS: Ber-EP4 reliably differentiates microcystic adnexal carcinoma from basal cell carcinoma to the same extent as it distinguishes the latter tumor from squamous cell carcinoma.
  • While it stains the majority of desmoplastic trichoepitheliomas, these tumors still have to be considered in the differential diagnosis with microcystic adnexal carcinoma, when Ber-EP4 is applied.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / diagnosis. Carcinoma, Skin Appendage / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Fluorescent Antibody Technique, Indirect. Humans. Sclerosis / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880584.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


59. Paavilainen V, Aaltonen M, Tuominen J, Saari KM: Histological characteristics of basal cell carcinoma of the eyelid. Ophthalmic Res; 2007;39(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological characteristics of basal cell carcinoma of the eyelid.
  • PURPOSE: To evaluate the histological subtypes of basal cell carcinoma (BCC) of the eyelid and to determine their effect on the size, depth of invasion and need of retreatment of a nonselected patient material seen in south-western Finland.
  • METHODS: We studied the case records and the histological characteristics of BCC of the eyelid treated at the Turku University Eye Clinic during the years 1988 through 1997.
  • The material consisted 103 patients (103 BCC tumors of the eyelid).
  • RESULTS: In 78.3% of the cases, the diameter of the lesion was smaller than 10 mm.
  • The most frequent histological subtype was nodular (84.5%) followed by sclerosing (5.8%), micronodular (4.9%), keratotic (2.9%) and superficial (1.9%) types of BCC of the eyelid.
  • Only patients of the nodular subtype showed recurrences (11 cases).
  • However, some nodular types of BCC tumors smaller than 10 mm in diameter extended to a depth of more than 4.0 mm.
  • CONCLUSIONS: The nodular subtype of BCC should be regarded as a potentially invasive and recurrent tumor.
  • Histopathological examination and subtyping of all BCC tumors is recommended.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164577.001).
  • [ISSN] 0030-3747
  • [Journal-full-title] Ophthalmic research
  • [ISO-abbreviation] Ophthalmic Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


60. Bostock-Ling N: Excising basal cell carcinoma in general practice. Aust Fam Physician; 2006 Jul;35(7):558-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excising basal cell carcinoma in general practice.
  • BACKGROUND: Currently there is much interest in the general practice management of basal cell carcinoma (BCC).
  • METHODS: A retrospective audit of histopathology reports from 91 excisions of BCCs.
  • RESULTS: Thirty-nine percent of BCCs in this series were located on the head or neck, compared with 75-94% from other series; 50% of BCCs from the head/neck contained an aggressive histological subtype, compared with only 10% from other sites; four out of 139 papers found regarding surgical management of BCCs were from primary care practice.
  • DISCUSSION: Significant differences exist between the location mix and histological types of BCCs treated in general practice with those reported in the research literature.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Family Practice / statistics & numerical data. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820836.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


61. Lupi O: Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Int J Dermatol; 2007 Nov;46(11):1113-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlations between the Sonic Hedgehog pathway and basal cell carcinoma.
  • The family received their name because when the D. melanogaster HH protein malfunctions the mutant fly ends up looking like a small prickly ball, similar to a curled up hedgehog.
  • The Sonic hedgehog (SHH) pathway is implicated in the etiology of the most common human cancer, the basal cell carcinoma (BCC).
  • Mutations in the receptor of SHH, the patched gene (PTCH), have been characterized in sporadic BCCs as well as those from patients with the rare genetic syndrome nevoid BCC.
  • Human PTCH is mutated in sporadic as well as hereditary BCCs, and inactivation of this gene is probably a necessary if not sufficient step for tumorigenesis.
  • Delineation of the biochemical pathway in which PTCH functions may lead to rational medical therapy for skin cancer and possibly other tumors.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Forkhead Transcription Factors / metabolism. Hedgehog Proteins / metabolism. Receptors, Cell Surface / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic. Humans. Mutation. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Signal Transduction. Veratrum Alkaloids / pharmacology

  • Genetics Home Reference. consumer health - PTCH1 gene.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988327.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SHH protein, human; 0 / SMO protein, human; 0 / Veratrum Alkaloids; 0 / patched receptors; ZH658AJ192 / cyclopamine
  • [Number-of-references] 35
  •  go-up   go-down


62. Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Försti A, Kumar R: No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol; 2007 Aug;157(2):375-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
  • BACKGROUND: The MDM2 oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumour suppressor protein.
  • This SNP was also found to be associated with the onset and risk of different cancer types.
  • Basal cell carcinoma of the skin (BCC) is one of the most common neoplasms in the world.
  • BCC development is associated with environmental factors (especially sun exposure) as well as heritable factors.
  • OBJECTIVES: The present case-control study investigated the association of the MDM2 SNP309 with the risk and the age at onset of BCC.
  • Methods Data from 509 individuals affected by BCC and 513 healthy controls were genotyped with TaqMan polymerase chain reaction.
  • RESULTS: Cases and controls showed a similar genotype distribution and the SNP did not modify the age at onset of BCC.
  • CONCLUSIONS: These results suggest that the MDM2 SNP309 alone affects neither the risk nor the age at onset of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Age of Onset. Aged. Aged, 80 and over. Case-Control Studies. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2008 Mar;158(3):636; author reply 636-7 [18076702.001]
  • (PMID = 17553029.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


63. Chai L, Tang J: [Analysis of 41 cases of basal cell carcinoma in maxillofacial area]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr;20(7):297-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of basal cell carcinoma in maxillofacial area].
  • OBJECTIVE: To explore the incidence, location and relationship between surgical margin and metastasis of basal cell carcinoma (BCC) in maxillofacial area.
  • METHOD: Retrospective study was undertaken of 41 cases of BCCs in the maxillofacial region diagnosed in histopathology during the period of 1996 to 2003.
  • RESULT: From 1996 to 2003, there were 41 cases of primary BBC in maxillofacial region, of whom 17 were males and 24 were females (male-to-female ratio, 1:1.41).
  • The age of BCCs patients was between 55-74 years old, the average age of female patients was 68.1 years old, and that of the male was 58.4 years old.
  • The lesions of BCCs were found in 13 cases in the nose (31.7%), 8 cases in scalp skin (19.5%), 7 cases in periorbital skin (17.1%), 7 cases in perioral region (17.1%), 4 cases in cheek skin (9.8%) and 2 cases in auricle skin (4.89%).
  • Of all the 41 patients, 4 patients were found to suffer regional lymph nodes metastasis or local bone destruction at the first visit (9.8%), 3 patients (7.3%) had a recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell. Facial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780141.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Alessi E, Venegoni L, Fanoni D, Berti E: Cytokeratin profile in basal cell carcinoma. Am J Dermatopathol; 2008 Jun;30(3):249-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin profile in basal cell carcinoma.
  • Origin of basal cell carcinoma (BCC) is still unclear.
  • We studied the cytokeratin (CK) profile in BCC using monoclonal antibodies against 12 CKs to further investigate the suggested origin of the tumor from follicular matrix cells or from follicular outer root sheath cells and to determine if BCC subtypes can be identified on the basis of their CK profiles.
  • Cases of pilomatricoma and samples of fetal skin served as controls to establish the CK profile in matrical cells and developing follicles during intrauterine life, that of the epidermis and cutaneous adnexa in adult life having been determined in a previous study.
  • The most significant findings were as follows: (a) CK 5 and CK 17 positivity in all the BCCs studied;.
  • (b) CK 7, CK 8, CK 18, and CK 19 positivity in 30/52, 33/52, 42/52, and 14/52 BCCs, respectively;.
  • (c) CK 14 negativity in almost all the BCCs studied; and (d) lack of CK 1 expression only in 2/2 morpheiform BCCs and 4/10 nodular BCCs.
  • The study suggests a tumorous differentiation toward follicular outer root sheath cells and, in most cases, also toward the glandular components of the pilosebaceous-apocrine unit.
  • No significant difference in the CK profile among the BCC subtypes studied was found.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Cell Transformation, Neoplastic. Fetus. Gestational Age. Hair Diseases / metabolism. Hair Diseases / pathology. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Keratinocytes / metabolism. Keratinocytes / pathology. Pilomatrixoma / metabolism. Pilomatrixoma / pathology. Skin / chemistry. Skin / embryology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496426.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


65. Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, Gupta G, Scottish Dermatological Society: Management of basal cell carcinoma by surveyed dermatologists in Scotland. Clin Exp Dermatol; 2006 Sep;31(5):648-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of basal cell carcinoma by surveyed dermatologists in Scotland.
  • BACKGROUND: The British Association of Dermatologists (BAD) has produced guidelines for management of basal cell carcinoma (BCC) in the UK.
  • OBJECTIVES: Our primary objectives were to assess the management of BCCs in Scotland and to compare it with BAD guidelines.
  • METHODS: In phase I of the audit, dermatologists in 14 centres across Scotland prospectively registered demographic and clinical data of all lesions suspected to be BCCs over a 6-week period between October and December 2000.
  • In phase II, details of management of these lesions were evaluated by case note review.
  • There were 524 clinically suspected BCCs seen in 470 patients; 164 lesions in 146 patients showed pathology other than BCC and were excluded from analysis, thus leaving 360 lesions available for analysis.
  • BCCs were equally distributed between the sexes, and lesions most commonly presented in those aged 71-80 years.
  • A diagnostic biopsy was taken in 22% of lesions, and the rest were treated definitively after a clinical diagnosis of BCC, of which 90% were confirmed on histology.
  • Nodulocystic lesions were the most common type of tumour, comprising 48% of lesions, and most BCCs were located on the head and neck region.
  • Correlation of the histological type of BCC and treatment received showed that nodulocystic and morpheic BCCs were managed as recommended.
  • There were more superficial BCCs treated with surgical excision than expected (22 of 34 lesions).
  • CONCLUSIONS: In general, BCCs are managed according to BAD guidelines in Scotland, but waiting times vary considerably.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901303.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


66. Lin LK, Lee H, Chang E: Pigmented basal cell carcinoma of the eyelid in Hispanics. Clin Ophthalmol; 2008 Sep;2(3):641-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented basal cell carcinoma of the eyelid in Hispanics.
  • BACKGROUND: Pigmented basal cell carcinoma (PBCC) of the eyelid has not been well cited in the literature, and is often overlooked in the differential diagnosis of pigmented eyelid lesions.
  • METHODS: Retrospective review of patients with eyelid skin cancer who presented to the Department of Dermatology at the Keck School of Medicine of the University of Southern California and the Doheny Eye Institute from January 2002 to November 2005.
  • RESULTS: Sixty-nine of the 79 patients with eyelid skin cancer had basal cell carcinoma.
  • CONCLUSIONS: Although eyelid PBCC is regarded as a rare condition, it may occur more commonly in the Hispanic population and should be remembered in the differential diagnosis of pigmented eyelid lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1996 May;34(5 Pt 1):751-2 [8632068.001]
  • [Cites] J Am Acad Dermatol. 1991 Dec;25(6 Pt 1):1005-11 [1810978.001]
  • [Cites] J Dermatol Surg Oncol. 1984 Nov;10(11):876-81 [6491026.001]
  • [Cites] Cancer. 1982 Oct 1;50(7):1440-6 [7104982.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):528-36 [11568742.001]
  • [Cites] Arch Ophtalmol (Paris). 1976 Oct;36(10):633-44 [139864.001]
  • [Cites] Arch Dermatol. 1973 Feb;107(2):206-7 [4685577.001]
  • [Cites] J Dermatol Surg. 1975 Mar;1(1):28-32 [1223142.001]
  • [Cites] Br J Dermatol. 1975 Oct;93(4):361-70 [1201188.001]
  • [Cites] Am J Ophthalmol. 1981 Aug;92(2):193-7 [7270632.001]
  • [Cites] Arch Dermatol. 1960 Jan;81:95-102 [13832072.001]
  • (PMID = 19668766.001).
  • [ISSN] 1177-5467
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2694027
  • [Keywords] NOTNLM ; eyelid / lesions / pigmented basal cell carcinoma / skin cancer
  •  go-up   go-down


67. Babaye-Nazhad S, Amirnia M, Alikhah H, Khodaeyani E, Atapour N: Safety margin in excision of basal cell carcinoma. Pak J Biol Sci; 2009 Nov 1;12(21):1408-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety margin in excision of basal cell carcinoma.
  • Fifty patients with basal cell carcinoma operated in Tabriz Sina hospital, were chosen randomly and pathological report of these patients after surgery was evaluated with consideration of presence of intact margin.
  • In pathologic report before operation of these patients, Basal cell carcinoma was certified.
  • Also, brief data of these patients history was studied from present cases.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20128511.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


68. Asgari MM, Tang J, Epstein EH Jr, Chren MM, Warton EM, Quesenberry CP Jr, Go AS, Friedman GD: Statin use and risk of basal cell carcinoma. J Am Acad Dermatol; 2009 Jul;61(1):66-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statin use and risk of basal cell carcinoma.
  • OBJECTIVE: We examined the association between statin use and basal cell carcinoma (BCC) risk.
  • METHODS: We identified all members of a large integrated health care delivery system with a diagnosis of a histologically proven BCC in 1997.
  • Subsequent BCCs were identified through 2006 from health plan electronic pathology records.
  • We used extended Cox regression to examine the independent association between receipt of statin therapy (ever vs never, cumulative duration) and risk of subsequent BCC.
  • RESULTS: Among 12,123 members given a diagnosis of BCC who had no prior statin exposure, 6381 developed a subsequent BCC during follow-up.
  • Neither "ever use of statins" (adjusted hazard ratio 1.02, 95% confidence interval: 0.92-1.12) or cumulative duration of statin (adjusted hazard ratio 1.02/year, 95% confidence interval: 0.99-1.11) was associated with subsequent BCC after adjustment for age, sex, and health care use.
  • There was also no significant association between use of non-statin antilipemics and subsequent BCC (adjusted hazard ratio 1.10, 95% confidence interval: 0.76-1.58).
  • LIMITATIONS: No information was available for BCC risk factors, such as sun sensitivity and sun exposure.
  • CONCLUSIONS: Among a large cohort of individuals with BCC, statin therapy was not significantly associated with risk of subsequent BCC.

  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] Am J Med. 2001 Jun 15;110(9):716-23 [11403756.001]
  • [Cites] Circulation. 2002 May 21;105(20):2341-6 [12021218.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):10-9 [12538446.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4808-17 [17001070.001]
  • [Cites] JAMA. 2006 Nov 1;296(17):2105-11 [17077375.001]
  • [Cites] N Engl J Med. 2007 Oct 11;357(15):1477-86 [17928595.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Nov 1;224(3):257-64 [17276471.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36 [17944002.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]
  • [Cites] Am J Epidemiol. 2008 Feb 15;167(4):492-9 [18056625.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1357-66 [18765432.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1343-56 [18765433.001]
  • [Cites] Int J Epidemiol. 2009 Feb;38(1):38-47 [18326513.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):425-9 [12637924.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 16;320(1):165-9 [15207716.001]
  • [Cites] Atherosclerosis. 2004 Aug;175(2):305-13 [15262187.001]
  • [Cites] JAMA. 1992 Jun 24;267(24):3305-10 [1597912.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Mol Carcinog. 1995 Apr;12(4):205-12 [7727042.001]
  • [Cites] Biochem J. 1995 Aug 15;310 ( Pt 1):305-9 [7646460.001]
  • [Cites] JAMA. 1996 Jan 3;275(1):55-60 [8531288.001]
  • [Cites] JAMA. 1998 May 27;279(20):1615-22 [9613910.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8408-13 [16707575.001]
  • [Cites] Free Radic Biol Med. 2006 Jul 15;41(2):339-46 [16814115.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):1082-4 [16924075.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1524-30 [11115165.001]
  • (PMID = 19464071.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / K24 AR052667; United States / NCI NIH HHS / CA / R01 CA 098838; United States / NIAMS NIH HHS / AR / K23 AR 051037; United States / NIAMS NIH HHS / AR / K23 AR051037-04; United States / NCI NIH HHS / CA / R01 CA098838; United States / NIAMS NIH HHS / AR / K23 AR051037; United States / NCI NIH HHS / CA / CA098838-04; United States / NIAMS NIH HHS / AR / K24 AR052667-04; United States / NIAMS NIH HHS / AR / AR052667-04; United States / NCI NIH HHS / CA / R01 CA098838-04; United States / NIAMS NIH HHS / AR / K24 AR 052667; United States / NIAMS NIH HHS / AR / AR051037-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • [Other-IDs] NLM/ NIHMS99847; NLM/ PMC2700205
  •  go-up   go-down


69. Puri T, Gunabushanam G, Sharma R, Kumar S, Julka PK: Extensive bone metastases from basal cell carcinoma of the eye. Singapore Med J; 2006 Sep;47(9):811-3
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive bone metastases from basal cell carcinoma of the eye.
  • The incidence of metastases from basal cell carcinoma is rare.
  • We report a 66-year-old woman who had basal cell carcinoma of the outer canthus of the left eye.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / pathology. Eye Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924365.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


70. Salas-Garcia I, Fanjul-Velez F, Ortega-Quijano N, Arce-Diego JL: Photodynamic effects on basal cell carcinoma with topical Photosensitizer. Conf Proc IEEE Eng Med Biol Soc; 2010;2010:2739-42
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic effects on basal cell carcinoma with topical Photosensitizer.
  • Photodynamic therapy (PDT) is a potential cancer therapy used in several clinical fields.
  • However, some cases of basal cell carcinoma show tumour persistence.
  • The poor response observed in this type of pathology, whose lesions penetrate in the deeper layers of the skin, could be attributed to an insufficient accumulation of the PS (Photosensitizer) in deeper tissues.
  • The development of accurate models could propose the adequate treatment dosimetry for those problematic cases in order to maximize the efficiency of the PDT treatment outcome.
  • In this work we present a PDT model that tries to predict the photodynamic effect on the skin affected by a basal cell carcinoma with a topically administered photosensitizer.
  • The results obtained allow us to know the evolution of the cytotoxic agent in order to estimate the necrotic area adjusting parameters such as the optical power, the photosensitizer concentration, the incubation and exposition time or the diffusivity and permeability of the damaged tissue.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Photochemotherapy / methods. Photosensitizing Agents / pharmacology. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21096212.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; S88TT14065 / Oxygen
  •  go-up   go-down


71. Gambichler T, Skrygan M, Hyun J, Bechara F, Tomi NS, Altmeyer P, Kreuter A: Cytokine mRNA expression in basal cell carcinoma. Arch Dermatol Res; 2006 Aug;298(3):139-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine mRNA expression in basal cell carcinoma.
  • There is evidence that cytokines (CKs) play a significant role in the development and/or progression of skin cancer.
  • The aim of the present study was to investigate the mRNA expression of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-8 in biopsy specimens of basal cell carcinoma (BCC), and to compare the results with the mRNA levels of non-lesional skin of BCC patients and healthy subjects.
  • Skin samples were obtained from 22 patients with BCC (lesional, non-lesional) and 25 healthy subjects (controls).
  • Histological examination revealed 12 nodular BCCs and 10 superficial BCCs.
  • The mRNA levels of CKs observed in healthy controls did not significantly (P > 0.05) differ from non-lesional CK levels of BCCs patients.
  • However, IL-6 and IL-8 levels of lesional skin were significantly (P < 0.05) higher than the CK levels observed in non-lesional skin and controls, respectively. mRNA expression of IL-6 and IL-8 showed a significant positive correlation (r = 0.51; P < 0.05).
  • There was no significant (P > 0.05) difference between lesional mRNA levels of TNF-alpha and those levels observed in non-lesional skin and controls.
  • The mRNA expression of CKs found in nodular and superficial BCCs did not significantly differ (P > 0.05).
  • BCC is associated with a significant increase of IL-6 and IL-8 expression.
  • In accordance with previous studies our data suggest a role for IL-6 and IL-8 in the development and/or progression of BCC, since mRNA expression of both CKs are significantly increased in tumour tissue.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cytokines / genetics. RNA, Messenger / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826314.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger
  •  go-up   go-down


72. Kostalevskaia AV, Petrunin DD, Romadanova NB, Snarskaia ES, Pal'tsev MA, Suchkov SV: [The current concept of immunological disorders in the case of basal-cell carcinoma]. Arkh Patol; 2008 Sep-Oct;70(5):42-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The current concept of immunological disorders in the case of basal-cell carcinoma].
  • Imbalance in the interaction of mechanisms of innate and adaptive immunity rather than selective defect of each of the links is a determinant of the development of basal-cell carcinoma of this or that form of immunopathology or that of transformation of one to another form.
  • The major tumor-associated immunological phenotypes are pathogenetically and clinically different, but have signs of two-link immunodeficiency in each case.
  • Predominant are autoimmune disorders involving mainly the adaptive link of immunological responsiveness in case of tumor-associated autoimmune syndrome concurrent with immunodeficiency.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Immunologic Deficiency Syndromes / etiology. Skin Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19137785.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


73. Jovanović M, Brasanac D, Rasulić L, Colić M, Stojicić M, Malis M: [The excision width in surgical treatment of basal cell carcinoma]. Acta Chir Iugosl; 2006;53(3):53-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The excision width in surgical treatment of basal cell carcinoma].
  • Basal cell carcinoma originates from pluripotent cells of basal layer of epiderm, external covering of hair follicles, sebaceous glands or other skin adnexa.
  • There are several types of basal cell carcinomas that may be manifested in over 12 clinical forms.
  • The analysis included 250 patients of both gender and different age, operated for basal cell carcinoma.
  • Clinical characteristics of basal cell carcinoma and the width of the excision were described.
  • It was concluded that the width of the excision of basal cell cancer was in relation to histological type.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338201.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


74. Jakobiec FA, Hanna E, Townsend DJ: Basal cell carcinoma of the eyelid with exceptional histomorphologic expressions. Ophthal Plast Reconstr Surg; 2009 May-Jun;25(3):232-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelid with exceptional histomorphologic expressions.
  • A basal cell carcinoma of the eyelid had unique and potentially confusing histopathologic features.
  • The tumor displayed a carcinoma in situ pattern with replacement of an extensive segment of the tarsal epithelium by neoplastic basaloid cells, a finding to the best of the authors' knowledge that has not been previously documented.
  • Within the infiltrating component of the dermis were classical solid basaloid nests and lobules; they were accompanied, however, by a separate and exceptionally prominent component of duct-like (pseudoglandular) units mimicking a microcystic adnexal carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454940.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Fan YS, Carr RA, Sanders DS, Smith AP, Lazar AJ, Calonje E: Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma. Histopathology; 2007 Jul;51(1):80-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma.
  • AIMS: There is considerable overlap between the histological features of sebaceoma and basal cell carcinoma (BCC).
  • The distinction between these two tumours is important due to the often more locally aggressive nature of BCC and the association of sebaceoma with the Muir-Torre syndrome.
  • The aim of this study was to describe the immunohistochemical reactivity of the cells in sebaceoma to Ber-EP4 and epithelial membrane antigen (EMA) and investigate the utility of this panel to differentiate sebaceoma from basal cell carcinoma.
  • A single case exhibited focal weak Ber-EP4 staining, predominantly in mature sebocytes and in < 10% of the tumour cells.
  • EMA was not expressed in the germinative cells of sebaceoma, but was expressed strongly in approximately 50% of mature sebocytes in all cases and highlighted the cytoplasmic vacuoles.
  • We reviewed the immunoreactivity of 51 cases of nodular BCCs and found moderate or strong BerEP4 expression in all cases with never less than 20% of the tumour staining.
  • Expression of EMA was uncommon in BCC (moderate or strong in 8%) and was confined to keratotic or squamoid areas.
  • CONCLUSION: The use of Ber-EP4 in combination with EMA, both widely used immunomarkers in histopathology, is a helpful aid in distinguishing sebaceoma from nodular BCC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Mucin-1 / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Sebaceous Glands / metabolism. Sebaceous Glands / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593083.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / human epithelial antigen-125
  •  go-up   go-down


76. Dissemond J, Grabbe S: [Non-surgical therapy of basal cell carcinoma of the head-neck region]. Laryngorhinootologie; 2006 Feb;85(2):133-41; quiz 142-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-surgical therapy of basal cell carcinoma of the head-neck region].
  • Basal cell carcinoma is a semi-malignant epithelial skin tumour with a locally destructive growth pattern but a very low tendency to metastases.
  • Basal cell carcinoma represent the most frequent malignant cutaneous tumour worldwide in white population with a lifetime risk of 30 % and still increasing incidence.
  • Basal cell carcinoma are predominantly located in the central region of the face.
  • The very rarely observed occurrence of metastases seems to be a result of insufficient therapy or a metatypic basal cell carcinoma type.
  • Therapy of first choice of basal cell carcinoma is the complete, micrographically controlled excision.
  • In addition, radiotherapy, topical immunotherapy with Imiquimod or photodynamic therapy may be considered as therapeutic alternatives in selected cases.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498544.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Interferon Inducers; 0 / Ointments; 144O8QL0L1 / Diclofenac; 8W8T17847W / Urea; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  • [Number-of-references] 15
  •  go-up   go-down


77. Thirumaran RK, Bermejo JL, Rudnai P, Gurzau E, Koppova K, Goessler W, Vahter M, Leonardi GS, Clemens F, Fletcher T, Hemminki K, Kumar R: Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. Carcinogenesis; 2006 Aug;27(8):1676-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin.
  • In addition to environmental exposures like UV radiation and, in some cases, arsenic contamination of drinking water, genetic factors may also influence the individual susceptibility to basal cell carcinoma of skin (BCC).
  • In the present study, 529 cases diagnosed with BCC and 533 controls from Hungary, Romania and Slovakia were genotyped for one polymorphism in each of seven DNA repair genes.
  • The variant allele for T241M (C>T) polymorphism in the XRCC3 gene was associated with a decreased cancer risk [odds ratio (OR), 0.73; 95% confidence interval (CI), 0.61-0.88; P = 0.0007, multiple testing corrected P = 0.004].
  • The risk of multiple BCC was significantly lower among variant allele carriers than in non-carriers (P = 0.04).
  • Men homozygous for the C-allele for E185Q (G>C) polymorphism in the NBS1 gene showed an increased BCC risk (OR, 2.19; 95% CI, 1.23-3.91), but not women (OR, 0.84; 95% CI, 0.49-1.47).
  • The data from this study show overall risk modulation of BCC by variant allele for T241M polymorphism in XRCC3 and gender-specific effect by E185Q polymorphism in NBS1.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA Repair. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cell Cycle Proteins / genetics. Child. Child, Preschool. Female. Genetic Predisposition to Disease. Genotype. Humans. Hungary / epidemiology. Male. Middle Aged. Nuclear Proteins / genetics. Odds Ratio. Risk Factors. Romania / epidemiology. Slovakia / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501254.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / NBN protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


78. Del Sordo R, Cavaliere A, Sidoni A: Basal cell carcinoma with matrical differentiation: expression of beta-catenin [corrected] and osteopontin. Am J Dermatopathol; 2007 Oct;29(5):470-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with matrical differentiation: expression of beta-catenin [corrected] and osteopontin.
  • Basal cell carcinoma with matrical differentiation is an extremely rare variant.
  • To date, only 12 cases have been described in the literature.
  • This tumor is a typical basal cell carcinoma with basaloid nests containing shadow cells identical to those of pilomatricoma and pilomatrical carcinoma.
  • We present two additional cases and have investigated the immunoprofile of .
  • The morphological and immunohistochemical features of these cases that we have found suggest that basal cell carcinomas with matrical differentiation belong to a spectrum of lesions deriving from hair follicles in which .
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Cell Transformation, Neoplastic / pathology. Osteopontin / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Dermatopathol. 2008 Jun;30(3):317
  • (PMID = 17890917.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin; 106441-73-0 / Osteopontin
  •  go-up   go-down


79. Izikson L, Bhan A, Zembowicz A: Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors. Am J Dermatopathol; 2005 Apr;27(2):91-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors.
  • Histologic differentiation between basal cell carcinoma and benign trichoblastic neoplasms such as trichoepithelioma and trichoblastoma can be difficult on small biopsies.
  • Recent studies have shown androgen receptor expression in a number of mature epithelial structures in the skin and in epithelial neoplasms including basal cell carcinoma.
  • These findings suggested that androgen receptor expression might be a useful adjunct in the histologic differential diagnosis between basal cell carcinoma and benign trichoblastic neoplasms.
  • Therefore, we performed immunohistochemical analysis of androgen receptor expression in 32 basal cell carcinomas and 10 benign trichoblastic tumors (6 trichoepitheliomas and 4 trichoblastomas).
  • In our study, at least focal expression of androgen receptor was detected in 78% of basal cell carcinomas.
  • These results confirm the lack of expression of androgen receptor in benign trichoblastic neoplasms and indicate that androgen receptor expression by tumor cells points to basal cell carcinoma as the most likely diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Hair Follicle / metabolism. Receptors, Androgen / biosynthesis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798431.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


80. Aguayo-Leiva IR, Ríos-Buceta L, Jaén-Olasolo P: [Surgical vs nonsurgical treatment of basal cell carcinoma]. Actas Dermosifiliogr; 2010 Oct;101(8):683-92
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical vs nonsurgical treatment of basal cell carcinoma].
  • [Transliterated title] Tratamiento quirúrgico vs. no quirúrgico en el carcinoma basocelular.
  • Numerous therapeutic options are now available for the treatment of basal cell carcinoma.
  • Then, based on the evidence reviewed, we attempt to provide an outline of the therapeutic strategies recommended in basal cell carcinoma, and the approach to be used in specific situations.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cryosurgery. Fluorouracil / therapeutic use. Follow-Up Studies. Hedgehog Proteins / antagonists & inhibitors. Humans. Interferons / therapeutic use. Laser Therapy. Mohs Surgery. Neoplasm Recurrence, Local. Photochemotherapy. Phytotherapy. Plant Preparations / therapeutic use. Risk Factors. Semecarpus. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Dermosifiliogr. 2011 Oct;102(8):633-4 [21798484.001]
  • (PMID = 20965011.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Hedgehog Proteins; 0 / Plant Preparations; 0 / SHH protein, human; 9008-11-1 / Interferons; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


81. Bath-Hextall FJ, Perkins W, Bong J, Williams HC: Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev; 2007;(1):CD003412
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for basal cell carcinoma of the skin.
  • BACKGROUND: Basal cell carcinoma (BCC) is the commonest skin cancer.
  • BCCs are slow-growing, locally invasive, epidermal skin tumours which mainly affect white skinned people.
  • OBJECTIVES: To assess the effects of treatments for basal cell carcinoma.
  • SEARCH STRATEGY: We searched the Cochrane Skin Group Specialised Register (January 2006), the Cochrane Central Register of Controlled Trials (The Cochrane LIbrary Issue 1, 2006), the Cochrane Database of Systematic Reviews (The Cochrane Library Issue 1, 2006), MEDLINE (2004 to January 2006), EMBASE (2005 to January 2006), the metaRegister of Controlled Trials (February 2006).
  • SELECTION CRITERIA: Inclusion criteria were adults with one or more histologically proven, primary basal cell carcinoma.
  • One study found no significant difference for recurrence at 30 months when Moh's micrographic surgery was compared to surgery for high risk facial BCCs, (RR 0.64, 95%CI 0.16,2.64).
  • When radiotherapy was compared to cryotherapy there were significantly fewer recurrences at one year in the radiotherapy group compared to the cryotherapy group.Short-term studies suggest a success rate of 87 to 88% for imiquimod in the treatment of superficial BCC using a once-daily regimen for 6 weeks and a 76% treatment response when treating nodular BCC for 12 weeks, when measured histologically.
  • AUTHORS' CONCLUSIONS: Overall there has been very little good quality research on treatments for BCC.
  • Most trials have only evaluated BCCs in low risk locations.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Cochrane Database Syst Rev. 2003;(2):CD003412 [12804465.001]
  • (PMID = 17253489.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 63
  •  go-up   go-down


82. Tanori M, Mancuso M, Pasquali E, Leonardi S, Rebessi S, Di Majo V, Guilly MN, Giangaspero F, Covelli V, Pazzaglia S, Saran A: PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma. Carcinogenesis; 2008 Oct;29(10):1911-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma.
  • The patched (Ptc1) protein is a negative regulator of sonic hedgehog signaling, a genetic pathway whose perturbation causes developmental defects and predisposition to specific malignant tumors.
  • Humans and mice with mutated Ptc1 are prone to medulloblastoma and basal cell carcinoma (BCC), both tumors showing dependence on radiation damage for rapid onset and high penetrance.
  • In addition to increased formation and slowed down kinetics of disappearance of gamma-H2AX foci, we observed increased apoptosis in PARP-1-deficient granule cell progenitors after irradiation.
  • Double-mutant mice were also strikingly more susceptible to BCC, with >50% of animals developing multiple, large, infiltrative tumors within 30 weeks of age.
  • [MeSH-major] Carcinoma, Basal Cell / prevention & control. Medulloblastoma / prevention & control. Poly(ADP-ribose) Polymerases / physiology. Receptors, Cell Surface / physiology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18660545.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histones; 0 / Receptors, Cell Surface; 0 / gamma-H2AX protein, mouse; 0 / patched receptors; EC 2.4.2.30 / Parp1 protein, mouse; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


83. Ericson MB, Wennberg AM, Larkö O: Review of photodynamic therapy in actinic keratosis and basal cell carcinoma. Ther Clin Risk Manag; 2008 Feb;4(1):1-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of photodynamic therapy in actinic keratosis and basal cell carcinoma.
  • The number of non-melanoma skin cancers is increasing worldwide, and so also the demand for effective treatment modalities.
  • Topical photodynamic therapy (PDT) using aminolaevulinic acid or its methyl ester has recently become good treatment options for actinic keratosis and basal cell carcinoma; especielly when treating large areas and areas with field cancerization.
  • This review covers the fundamental aspects of topical PDT and its application for treatment of actinic keratosis and basal cell carcinoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):11-7 [10607351.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6164-70 [10626808.001]
  • [Cites] Photochem Photobiol. 2000 May;71(5):640-7 [10818796.001]
  • [Cites] Photochem Photobiol. 2000 Jun;71(6):724-9 [10857368.001]
  • [Cites] Clin Exp Dermatol. 2000 Jun;25(4):317-22 [10971495.001]
  • [Cites] Photochem Photobiol. 2000 Dec;72(6):794-802 [11140268.001]
  • [Cites] Photochem Photobiol. 2001 Feb;73(2):164-9 [11272730.001]
  • [Cites] J Photochem Photobiol B. 2000 Nov;58(2-3):149-55 [11233643.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):567-74 [11260016.001]
  • [Cites] J Am Acad Dermatol. 2001 Jul;45(1):96-104 [11423841.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):493-7 [12372093.001]
  • [Cites] Clin Dermatol. 2002 Sep-Oct;20(5):571-81 [12435528.001]
  • [Cites] J Am Acad Dermatol. 2003 Feb;48(2):227-32 [12582393.001]
  • [Cites] J Photochem Photobiol B. 2003 Feb;69(2):121-7 [12633984.001]
  • [Cites] Photochem Photobiol. 2003 Mar;77(3):319-23 [12685661.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1727-30 [12702551.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1462-9 [12778078.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2003 Jun;19(3):134-41 [12914598.001]
  • [Cites] Photochem Photobiol. 1990 Aug;52(2):375-85 [2145595.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] Radiat Res. 1991 Jun;126(3):296-303 [2034787.001]
  • [Cites] J Am Acad Dermatol. 1992 May;26(5 Pt 1):720-6 [1583171.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] Int J Cancer. 1992 Sep 30;52(3):433-43 [1399120.001]
  • [Cites] J Photochem Photobiol B. 1992 Jul 30;14(4):275-92 [1403373.001]
  • [Cites] J Photochem Photobiol B. 1992 Jul 15;14(3):159-76 [1432388.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1249-54 [8443805.001]
  • [Cites] Cell Biol Toxicol. 1993 Jan-Mar;9(1):95-105 [8390914.001]
  • [Cites] Epithelial Cell Biol. 1992 Jan;1(1):47-51 [1307938.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):21-8 [8018536.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):826-33 [7947087.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]
  • [Cites] Cancer Lett. 1995 Jul 13;93(2):227-32 [7621433.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):282-8 [7547399.001]
  • [Cites] Arch Dermatol. 2003 Sep;139(9):1173-7 [12975159.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Annu Rev Phys Chem. 1996;47:555-606 [8930102.001]
  • [Cites] J Photochem Photobiol B. 1996 Sep;35(3):209-11 [8933726.001]
  • [Cites] Photochem Photobiol. 1997 Feb;65(2):235-51 [9066303.001]
  • [Cites] J Am Acad Dermatol. 1997 May;36(5 Pt 1):742-6 [9146537.001]
  • [Cites] Br J Cancer. 1998;77(2):235-42 [9460994.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Br J Cancer. 1998 May;77(9):1386-94 [9652753.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):679-82 [9744510.001]
  • [Cites] Photochem Photobiol. 1998 Nov;68(5):675-8 [9825697.001]
  • [Cites] Photochem Photobiol. 1999 Jan;69(1):61-70 [10063801.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Acta Derm Venereol. 1999 Sep;79(5):370-2 [10494714.001]
  • [Cites] J Chemother. 2004 Oct;16(5):491-3 [15565918.001]
  • [Cites] Br J Dermatol. 2004 Dec;151(6):1204-12 [15606516.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):33-6; discussion 36-7 [15720093.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Dermatol Surg. 2005 Mar;31(3):375-8 [15841647.001]
  • [Cites] J Control Release. 2005 Sep 2;106(3):350-60 [15967535.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5):823-7 [16243131.001]
  • [Cites] Eur J Pharm Sci. 2006 Feb;27(2-3):268-79 [16330192.001]
  • [Cites] J Invest Dermatol. 2006 Feb;126(2):265-71 [16374471.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1297-9 [14674917.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):63-6 [14692930.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Jan 13;56(1):77-94 [14706446.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):115-21 [14724445.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):116-20 [14732670.001]
  • [Cites] Br J Dermatol. 2004 Jan;150(1):143-5 [14746630.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):264-71 [14871220.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):337-40 [14996106.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1061-9 [15214890.001]
  • [Cites] Br J Dermatol. 2004 Sep;151(3):653-5 [15377353.001]
  • [Cites] Lancet. 1972 Dec 2;2(7788):1175-7 [4117595.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 1):2326-9 [1277137.001]
  • [Cites] Cancer Res. 1978 Aug;38(8):2628-35 [667856.001]
  • [Cites] Biochem J. 1984 Oct 15;223(2):441-5 [6497856.001]
  • [Cites] Cancer Res. 1985 Apr;45(4):1608-10 [3978628.001]
  • [Cites] Photochem Photobiol. 1986 Nov;44(5):679-87 [3809258.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2297-300 [3179945.001]
  • [Cites] Semin Hematol. 1988 Oct;25(4):282-302 [3064310.001]
  • [Cites] Am J Pathol. 1990 Apr;136(4):891-7 [2327473.001]
  • [Cites] Photochem Photobiol. 1996 May;63(5):608-14 [8628752.001]
  • [Cites] Arch Dermatol Res. 1996 Sep;288(10):561-4 [8919036.001]
  • [Cites] Lasers Surg Med. 2006 Jan;38(1):22-5 [16392149.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Br J Pharmacol. 2006 Apr;147(7):825-33 [16432502.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] J Drugs Dermatol. 2006 Apr;5(4):353-6 [16673803.001]
  • [Cites] Dermatol Surg. 2006 Jun;32(6):795-801; discussion 801-3 [16792644.001]
  • [Cites] Acta Derm Venereol. 2006;86(5):404-8 [16955183.001]
  • [Cites] Acta Derm Venereol. 2006;86(5):409-11 [16955184.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1262-9 [17107399.001]
  • [Cites] J Invest Dermatol. 2006 Dec;126(12):2679-86 [16841035.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):35-6 [17254035.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1647-56 [17380113.001]
  • (PMID = 18728698.001).
  • [ISSN] 1176-6336
  • [Journal-full-title] Therapeutics and clinical risk management
  • [ISO-abbreviation] Ther Clin Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2503644
  • [Keywords] NOTNLM ; actinic keratosis / basal cell carcinoma / photodynamic therapy
  •  go-up   go-down


84. Forman SB, Ferringer TC, Garrett AB: Basal cell carcinoma of the nail unit. J Am Acad Dermatol; 2007 May;56(5):811-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the nail unit.
  • We report a case of a 70-year-old white male with a basal cell carcinoma of the left thumb nail unit.
  • The defect was repaired with a full thickness skin graft.
  • Prior to this report, 21 cases of basal cell carcinoma have been reported in the world literature.
  • This case, as well as the prior reports, are reviewed with a focus on time to diagnosis, location, excisional technique, and method of repair.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437888.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Mosterd K, Arits AH, Thissen MR, Kelleners-Smeets NW: Histology-based treatment of basal cell carcinoma. Acta Derm Venereol; 2009;89(5):454-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology-based treatment of basal cell carcinoma.
  • Basal cell carcinoma is the most common type of skin cancer and its incidence is still rising.
  • Selection criteria were histological subtype, primary or recurrent basal cell carcinoma and tumour localization.
  • Although surgery remains the preferred treatment for most basal cell carcinomas, patient and tumour characteristics should be taken into account when choosing the most suitable treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Cryotherapy. Mohs Surgery. Photochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Evidence-Based Medicine. Humans. Neoplasm Invasiveness. Patient Selection. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Derm Venereol. 2009;89(5):450-2 [19734965.001]
  • [ErratumIn] Acta Derm Venereol. 2009 Nov;89(6):667
  • (PMID = 19734968.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


86. Celić D, Lipozencić J, Jurakić Toncić R, Ledić-Drvar D, Marasović D, Puizina-Ivić N, Cabrijan L, Bradamante M: The incidence of basal cell carcinoma in Croatia: an epidemiological study. Acta Dermatovenerol Croat; 2009;17(2):108-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of basal cell carcinoma in Croatia: an epidemiological study.
  • The aim of the study was to investigate the basal cell carcinoma (BCC) incidence in Croatia in the 2003-2005 period.
  • Data were collected from University Department of Dermatology and Venereology, Zagreb University Hospital Center and National Cancer Registry.
  • In the study period, there were 7,244 BCC cases (3,519 men and 3,725 women) in Croatia.
  • The head and neck were almost exclusive localizations of BCC.
  • The highest BCC incidence was recorded in Zadar County.
  • The incidence of BCC was high in both littoral and inland counties of Croatia.
  • Study results will serve as reference figures on studying the trend of BCC incidence in Croatia and Europe in the forthcoming years.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595266.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


87. Segerbäck D, Strozyk M, Snellman E, Hemminki K: Repair of UV dimers in skin DNA of patients with basal cell carcinoma. Cancer Epidemiol Biomarkers Prev; 2008 Sep;17(9):2388-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repair of UV dimers in skin DNA of patients with basal cell carcinoma.
  • Epidemiologic studies suggest that exposure to sunlight is the primary etiologic agent for basal cell carcinoma.
  • Formation of UV-induced DNA damage is believed to be a crucial event in the process leading to skin cancer.
  • In this study, repair of photoproducts in DNA was followed in the skin of patients with basal cell carcinoma and control subjects.
  • The subjects were exposed to 800 J/m(2) Commission Internationale de 1'Eclairag of solar-simulating radiation on buttock skin.
  • The levels of TT=T in patients with basal cell carcinoma and controls were similar (9.9 +/- 4.0 and 9.2 +/- 2.9 products per 10(6) normal nucleotides), whereas the level of TT=C was significantly lower in controls than in patients with basal cell carcinoma (6.2 +/- 3.1 versus 10.9 +/- 4.5 products per 10(6) normal nucleotides).
  • The fractions of TT=T remaining after 24 hours and 3 weeks were significantly higher in patients with basal cell carcinoma (72% and 11%) compared with controls (48% and 5%).
  • A slower removal in patients with basal cell carcinoma than in controls was indicated also for TT=C (52% versus 42% remaining at 24 hours); however, the difference between groups was not significant.
  • When including data from our previously reported small-scale study, the fraction of dimers remaining at 24 hours was significantly higher in patients with basal cell carcinoma for both TT=C and TT=T.
  • The data suggest that patients with basal cell carcinoma have a reduced capacity to repair UV-induced DNA lesions.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. DNA Repair. DNA, Neoplasm / metabolism. Pyrimidine Dimers / metabolism. Skin / radiation effects. Skin Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Buttocks. Case-Control Studies. Chromatography, High Pressure Liquid. DNA Damage. Female. Humans. Male. Middle Aged. Risk. Sunlight

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18768508.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Pyrimidine Dimers
  •  go-up   go-down


88. Gore SM, Kasper M, Williams T, Regl G, Aberger F, Cerio R, Neill GW, Philpott MP: Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation? J Pathol; 2009 Sep;219(1):61-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation?
  • Although deregulated Hedgehog signalling and elevated Gli transcription factor expression are known to promote the development of basal cell carcinoma (BCC), little is known about molecular mechanisms driving the development of specific growth pattern subtypes.
  • We asked whether neuronal differentiation is a characteristic of BCC and whether there is any correlation with BCC subtype.
  • Using RT-PCR and immunohistochemistry, we confirmed that the neuronal markers ARC, beta-tubulin III, GAP-43 and Neurofilament are expressed in human BCC but not in normal epidermis.
  • Moreover, we found that expression of these neuronal differentiation markers showed strong correlation to BCC subtype, with more aggressive infiltrative and morphoeic BCC showing low levels or lack of expression compared to nodular, superficial and micronodular subtypes.
  • Primary human keratinocytes retrovirally expressing GLI1(-) and GLI2(-) showed elevated levels of beta-tubulin III and ARC but not Neurofilament or GAP-43, suggesting that beta-tubulin III and Arc may be early targets of aberrant Gli expression in BCC, whereas expression of Neurofilament and GAP-43 are either later, downstream targets or under control of alternative pathways.
  • We propose that neuronal differentiation is a feature of BCC and that expression of these markers is in part due to aberrant Hedgehog signalling.
  • Moreover, we suggest that correlation between loss of expression of neuronal markers in infiltrative and morphoeic BCC subtypes reflects dedifferentiation of more aggressive BCC subtypes.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Gene Expression Regulation, Neoplastic. Hedgehog Proteins / genetics. Neurons / pathology
  • [MeSH-minor] Analysis of Variance. Biomarkers / analysis. Case-Control Studies. Cell Differentiation. Cells, Cultured. Cytoskeletal Proteins / genetics. GAP-43 Protein / genetics. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Keratinocytes / metabolism. Kruppel-Like Transcription Factors / genetics. Nerve Tissue Proteins / genetics. Neurofilament Proteins / genetics. Neuronal Plasticity. Nuclear Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction / physiology. Transcription Factors / genetics. Transduction, Genetic. Tubulin / genetics. Zinc Finger Protein GLI1

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479712.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 20652; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytoskeletal Proteins; 0 / GAP-43 Protein; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tubulin; 0 / Zinc Finger Protein GLI1; 0 / activity regulated cytoskeletal-associated protein
  •  go-up   go-down


89. Marra DE, Torres A, Schanbacher CF, Gonzalez S: Detection of residual basal cell carcinoma by in vivo confocal microscopy. Dermatol Surg; 2005 May;31(5):538-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of residual basal cell carcinoma by in vivo confocal microscopy.
  • BACKGROUND: Near-infrared reflectance-mode confocal scanning laser microscopy (RCM) represents a novel imaging technique for microscopic analysis of skin lesions and may provide a noninvasive modality for the diagnosis of basal cell carcinoma (BCC).
  • OBJECTIVE: To determine the feasibility of detecting residual or clinically equivocal BCC using RCM.
  • METHODS: In this pilot study, RCM was used in three cases to characterize the histologic features of index lesions in vivo.
  • RESULTS: Evaluation of clinically equivocal lesions by RCM revealed features characteristic of BCC, including tightly packed nests of elongated, monomorphic, polarized nuclei and subjacent ectatic blood vessels with lymphocytes undergoing margination and rolling.
  • Conventional histology confirmed the presence of BCC in all cases.
  • CONCLUSION: We report the use of RCM in the confirmation of residual BCC in two cases and the tentative diagnosis with subsequent pathologic conformation of a third case in which a biopsy was previously inadequate.
  • Our results demonstrate that confocal microscopy may facilitate diagnosis of BCC in vivo and warrant further prospective study to quantify the sensitivity and specificity of this rapidly evolving imaging modality.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Arm. Diagnosis, Differential. Face. Forehead. Humans. Male. Microscopy, Confocal. Middle Aged. Pilot Projects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962737.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Ruiz Lascano A, Kuznitzky R, Garay I, Ducasse C, Albertini R: [Risk factors for basal cell carcinoma. Case-control study in Cordoba]. Medicina (B Aires); 2005;65(6):495-500
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk factors for basal cell carcinoma. Case-control study in Cordoba].
  • [Transliterated title] Factores de riesgo para carcinoma basocelular. Estudio de casos-controles en Córdoba.
  • Basal cell carcinoma is undoubtedly a complex disease.
  • We assessed potential risk factors for basal cell carcinoma in a population from Córdoba (Argentina).
  • This case-control study involved 88 newly diagnosed cases and 88 controls, matched by age and sex.
  • The following risk factors were significant in the multivariate analysis: skin type I-II-III, high recreational sun exposure after 20 years of age, high sun exposure for beach holidays and actinic keratosis.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Skin Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433475.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


91. Navarrete Isidoro O, Abad Fernández A, López Vime R, Jara Chinarro B, Juretschke Moragues MA: [Pulmonary metastasis of Basal cell carcinoma of the skin]. Arch Bronconeumol; 2005 Mar;41(3):169-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastasis of Basal cell carcinoma of the skin].
  • [Transliterated title] Metástasis pulmonares de un carcinoma basocelular cutáneo.
  • Basal cell carcinoma of the skin is a common neoplasm usually considered benign.
  • We report the case of a 41-year old man diagnosed with lung metastasis secondary to base cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Lung Neoplasms / secondary. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15766469.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


92. Misago N, Mori T, Narisawa Y: Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Nov;24(11):1354-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma.
  • BACKGROUND: Both trichoblastoma and basal cell carcinoma (BCC) are considered to be a benign and malignant neoplasm of follicular germinative cells respectively.
  • OBJECTIVE: The aim of the present study was to investigate whether trichoblastoma and BCC recapitulate the epithelial–mesenchymal interactions in embryonic hair germs or early anagen hair follicles by expressing nestin in stromal cells.
  • METHODS: Immunohistochemical staining was performed with antibody against nestin for 15 trichoblastomas including large/small nodular, retiform and trichoepithelioma types, while adding the superficial type associated with nevus sebaceous and for 20 BCCs including superficial, nodular, nodulo-infiltrative, and infiltrative/micronodular types.
  • In all 20 BCCs, the stromal cells were basically negative for nestin.
  • CONCLUSIONS: The development of trichoblastomas incompletely recapitulates the epithelial–mesenchymal interactions in embryonic hair germs or early anagen hair follicles, whereas BCCs fundamentally have lost this ability.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. Sebaceous Gland Neoplasms / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337823.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


93. Jankovic I, Kovacevic P, Visnjic M, Jankovic D, Binic I, Jankovic A: Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence? An Bras Dermatol; 2010 Nov-Dec;85(6):872-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence?
  • INTRODUCTION: Basal cell carcinoma is the most common tumor of the eyelid.
  • In this region, reconstruction is complex and damage to healthy tissue should be minimal.
  • OBJECTIVE: To define the relationship between margin clearance at excision and the recurrence rate of basal cell carcinoma of the eyelid.
  • METHODS: This prospective study was conducted with 111 patients submitted to surgery for basal cell carcinoma of the eyelid between 2001 and 2003 and followed up for a period of five years.
  • RESULTS: No significant association was found between incomplete tumor excision and recurrence except in patients under 56 years of age, female patients and in the case of tumors of the medial canthus.
  • CONCLUSION: A risk of recurrence in incompletely excised basal cell carcinomas of the eyelid was only confirmed in younger patients, females and for tumors of the medial canthus.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Bras Dermatol. 2011 Mar-Apr;86(2):401; author reply 401-3 [21603839.001]
  • (PMID = 21308312.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


94. Smirnova IO: [Skin photoaging and basal cell carcinoma: the role of mast cells]. Klin Med (Mosk); 2005;83(7):55-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin photoaging and basal cell carcinoma: the role of mast cells].
  • The authors examined 37 patients with basal cell carcinoma (BCC) and analyzed 106 observation records.
  • The aim of the study was to determine the influence of insolation on the incidence of BCC and the role of mast cells in its development (their hyperplasia).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mast Cells / pathology. Skin Aging. Skin Neoplasms / pathology
  • [MeSH-minor] Age Factors. Aged. Cell Division. Female. Humans. Incidence. Male. Retrospective Studies. Risk Factors. Sex Distribution

  • MedlinePlus Health Information. consumer health - Skin Aging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117428.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


95. Ly E, Piot O, Durlach A, Bernard P, Manfait M: Polarized Raman microspectroscopy can reveal structural changes of peritumoral dermis in basal cell carcinoma. Appl Spectrosc; 2008 Oct;62(10):1088-94
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polarized Raman microspectroscopy can reveal structural changes of peritumoral dermis in basal cell carcinoma.
  • This technique is used for the first time on a human skin section to probe the molecular modifications of the surrounding dermis in superficial basal cell carcinoma.
  • We see polarized Raman microspectroscopy as a potential tool that could be implemented for clinical analyses to guide clinicians and surgeons in the treatment of aggressive skin cancers.
  • The information obtainable could also help better elucidate the molecular mechanisms induced in basal cell carcinoma development.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Microscopy, Polarization / methods. Skin Neoplasms / pathology. Spectrum Analysis, Raman / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926017.001).
  • [ISSN] 0003-7028
  • [Journal-full-title] Applied spectroscopy
  • [ISO-abbreviation] Appl Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Rossman D, Arthurs B, Odashiro A, Saraiva V, Burnier M Jr: Basal cell carcinoma of the caruncle. Ophthal Plast Reconstr Surg; 2006 Jul-Aug;22(4):313-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the caruncle.
  • An 82-year-old white man presented with a 2- to 3-month history of a lesion in his left medial canthal region.
  • Surgical excision of the lesion was performed, and histopathology showed a nodular basal cell carcinoma of the caruncle.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Conjunctival Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855514.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Gambichler T, Skrygan M, Huyn J, Bechara FG, Sand M, Altmeyer P, Kreuter A: Pattern of mRNA expression of beta-defensins in basal cell carcinoma. BMC Cancer; 2006;6:163
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of mRNA expression of beta-defensins in basal cell carcinoma.
  • BACKGROUND: Although the human beta-defensins hBDs today seem to have diverse functional activities in innate antimicrobial immunity, a few reports also indicated an altered expression of these antimicrobial peptides (AMPs) in tissues of cancers such as oral squamous cell carcinoma.
  • The present work was aimed on the study of hBD gene expression in basal cell carcinoma (BCC) which is the most common cancer in humans.
  • METHODS: Twenty-two non-ulcerated BCCs (12 nodular type, 10 superficial type) have been analysed for the presence of hBD (1-3) mRNA by quantitative real-time RT-PCR.
  • As controls, non-lesional skin specimens of BCC patients as well as samples of healthy subjects were assessed by RT-PCR.
  • RESULTS: hBD-1 levels in healthy controls and non-lesional skin of BCC patients were significantly (P < 0.05) higher than the levels observed in tumour tissue.
  • Moreover, BCCs showed significantly (P < 0.05) increased mRNA expression of hBD-2 as compared to controls.
  • The mRNA expression of hBDs (1-3) found in nodular and superficial BCCs did not significantly (P > 0.05) differ.
  • CONCLUSION: The gene expression patterns of hBD-1 and hBD-2 are for the first time shown to be significantly altered in non-ulcerated BCCs as compared to intra-individual and inter-individual controls, respectively.
  • The present findings may indicate that beside the antimicrobial activity of AMPs, hBDs may also play a role in the pathogenesis of BCC.
  • However, functional and immunohistological studies investigating hBDs in patients with BCC are needed to confirm our data.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Skin Neoplasms / metabolism. beta-Defensins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1125-7 [10810407.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1275-8 [17107401.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1311-24 [11943716.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):79-84 [12680197.001]
  • [Cites] Lab Invest. 2003 Apr;83(4):501-5 [12695553.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7515-9 [14612553.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4629-33 [14981906.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):181-6 [15202832.001]
  • [Cites] Eur J Med Res. 1998 Jul 20;3(7):315-23 [9682027.001]
  • [Cites] Cancer Lett. 1999 Aug 23;143(1):37-43 [10465335.001]
  • [Cites] Science. 1999 Oct 15;286(5439):525-8 [10521347.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):328-30 [15627069.001]
  • [Cites] BMC Cancer. 2005 Jan 19;5:8 [15656915.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4051-7 [15736451.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):381-90; quiz 391-2 [15761415.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):181-92 [15978322.001]
  • [Cites] Skin Res Technol. 2005 Aug;11(3):196-200 [15998331.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] J Invest Dermatol. 2005 Dec;125(6):1163-73 [16354186.001]
  • [Cites] Methods. 2001 Dec;25(4):386-401 [11846608.001]
  • (PMID = 16796735.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / beta-Defensins
  • [Other-IDs] NLM/ PMC1538617
  •  go-up   go-down


98. Stoecker WV, Gupta K, Shrestha B, Wronkiewiecz M, Chowdhury R, Stanley RJ, Xu J, Moss RH, Celebi ME, Rabinovitz HS, Oliviero M, Malters JM, Kolm I: Detection of basal cell carcinoma using color and histogram measures of semitranslucent areas. Skin Res Technol; 2009 Aug;15(3):283-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of basal cell carcinoma using color and histogram measures of semitranslucent areas.
  • BACKGROUND: Semitranslucency, defined as a smooth, jelly-like area with varied, near-skin-tone color, can indicate a diagnosis of basal cell carcinoma (BCC) with high specificity.
  • This study sought to analyze potential areas of semitranslucency with histogram-derived texture and color measures to discriminate BCC from non-semitranslucent areas in non-BCC skin lesions.
  • METHODS: For 210 dermoscopy images, the areas of semitranslucency in 42 BCCs and comparable areas of smoothness and color in 168 non-BCCs were selected manually.
  • Six color measures and six texture measures were applied to the semitranslucent areas of the BCC and the comparable areas in the non-BCC images.
  • RESULTS: Receiver operating characteristic (ROC) curve analysis showed that the texture measures alone provided greater separation of BCC from non-BCC than the color measures alone.
  • CONCLUSION: Texture and color analysis measures, especially smoothness, may afford automatic detection of BCC images with semitranslucency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2003 Mar;7(1):47-64 [12467721.001]
  • [Cites] Skin Res Technol. 2003 Feb;9(1):73-80 [12535288.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):679-93 [12734496.001]
  • [Cites] Comput Med Imaging Graph. 2003 Sep-Oct;27(5):387-96 [12821032.001]
  • [Cites] Dermatology. 2004;208(1):21-6 [14730232.001]
  • [Cites] Stud Health Technol Inform. 2002;90:509-13 [15460746.001]
  • [Cites] Arch Dermatol. 2009 Feb;145(2):224 [19221287.001]
  • [Cites] Comput Med Imaging Graph. 1992 May-Jun;16(3):191-7 [1623494.001]
  • [Cites] Comput Med Imaging Graph. 1998 Sep-Oct;22(5):375-89 [9890182.001]
  • [Cites] Skin Res Technol. 2005 Aug;11(3):179-84 [15998328.001]
  • [Cites] Arch Dermatol. 2006 Sep;142(9):1211-2 [16983009.001]
  • [Cites] Arch Dermatol. 2007 Mar;143(3):329-38 [17372097.001]
  • [Cites] Comput Med Imaging Graph. 2008 Dec;32(8):670-7 [18804955.001]
  • [Cites] Comput Biomed Res. 1984 Jun;17(3):241-7 [6375947.001]
  • (PMID = 19624424.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R44 CA101639; United States / NCI NIH HHS / CA / R44 CA101639-02A2; United States / NCI NIH HHS / CA / R44 CA-101639-02A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS132816; NLM/ PMC3154079
  •  go-up   go-down


99. Braun-Falco M: Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type. J Cutan Pathol; 2007 Sep;34(9):731-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type.
  • BACKGROUND: The combination of malignant melanoma (MM) and basal cell carcinoma (BCC) within a single tumor is an unusual finding.
  • CASE REPORT: An 84-year-old white man with a pigmented tumor on the back showing a combination of MM and BCC.
  • Histopathologically, the lesions turned out to be a combined tumor consisting of a superficial BCC and a regressive MM with a tumor thickness of 1.25 mm.
  • The conglomerates of the BCC lay within the MM and were admixed with a high number of Melan-A-positive melanocytic cells.
  • CONCLUSION: By reviewing the low number of published cases, we found that a combined MM-BCC tumor exists in two variants: a collision type in which components of each cell type are clearly demarcated and an intermingled type in which both cell types grow intimately together.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696923.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


100. Son SW, Park SY, Park GM, Ha SH, Lee GW, Lee OS, Hwu Y, Kim AR, Je JH, Oh CH: Ex vivo imaging of basal cell carcinoma using synchrotron phase-contrast X-ray microscopy. Skin Res Technol; 2008 Feb;14(1):13-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo imaging of basal cell carcinoma using synchrotron phase-contrast X-ray microscopy.
  • BACKGROUND/AIMS: There is a need for development of non-invasive methods to improve early diagnosis and screening of suspected malignant lesions.
  • Phase-contrast X-ray microscopy (PCXM) has potential to reveal the structures inside soft tissues, and fine details can be observed without any staining or contrast-enhancing cell preparation.
  • We aimed to investigate the possibility that PCXM can be used to explore the microscopic details of basal cell carcinoma (BCC).
  • METHODS: Paraffin blocks of specimens from patients with basal cell carcinoma were cut with 30 microm thickness for PCXM imaging.
  • The images taken with this technique showed clear anatomic details of organelles in normal skin such as epidermis, dermis and skin appendages.
  • CONCLUSION: In this pilot study, we successfully demonstrated that synchrotron PCXM could be used for radiological imaging of BCC with great anatomic details.
  • [MeSH-major] Neoplasms, Basal Cell / radiography. Skin / radiography. Skin Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211597.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down






Advertisement